Use of cyclosporine analogues as antithrombotic agents.
Patent Information
- Application Number
- JP2023532524
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-29
- Filing Date
- 2021-11-26
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current antithrombotic agents used for treating blood clots are associated with a high risk of bleeding and lack effectiveness in preventing thrombosis without significant bleeding complications.
The use of cyclosporine analogs, such as CRV431, to inhibit procoagulant platelet formation without affecting platelet aggregation, thereby reducing blood clot formation and thrombosis risk.
Cyclosporine analogs effectively reduce blood clot formation by up to 95% and delay clot onset, while minimizing the risk of bleeding, making them a safer alternative to traditional antithrombotic agents.
Smart Images

Figure 2022115651000001 
Figure 2022115651000002 
Figure 2022115651000003
Abstract
Description
Technical Field
[0001] Cross - reference documents This application claims the benefit of priority to U.S. Provisional Application No. 63 / 118,947, filed November 29, 2020, the contents of which are hereby incorporated by reference in their entirety. The present disclosure generally relates to the fields of molecular biology and medicine. One aspect relates to reducing the formation of blood clots (thrombi) using cyclophilin inhibitors.
Background Art
[0002] Thrombosis occurs in response to injury or other signals that lead to the recruitment of platelets to the site of injury. Platelets form a plug by adhering to the site of injury and are a major component of blood clotting. In addition, coagulation factors are released that further activate platelets and generate protein fibrin, another major component of blood clotting. In the coagulation pathway, the extrinsic pathway is activated by external injury, while the intrinsic pathway is activated by trauma within the vascular system. Both of these converge on a common pathway to promote blood clotting. Three classes of drugs are currently used for the treatment of thrombosis. The two main ones are anticoagulants and anti - platelet agents. The third class, thrombolytics, target fibrin and are used to dissolve blood clots. Thrombolytics are typically used in emergency situations (e.g., stroke), and then, because they can induce severe bleeding and even intracerebral hemorrhage, they are used rarely. Anticoagulant therapy inhibits proteolytic signaling pathways that induce fibrin production and promote platelet activation. These anticoagulant therapies include drugs such as warfarin that target the intrinsic pathway of the coagulation response. Anti - platelet therapy can block platelet activation and aggregation. Anti - platelet therapy includes aspirin, which inhibits an enzyme important for platelet activation. Many of these drugs can be associated with dangerous bleeding. There is a need to find antithrombotic agents that are effective in preventing blood clotting and thrombosis but do not cause bleeding as much as current treatments. [Overview of the project]
[0003] Disclosed herein are methods for reducing or preventing the formation of blood clots (thrombi), methods for treating thromboembolic disorders, methods for primary or secondary prevention of thromboembolic disorders, and methods for reducing or inhibiting platelet formation. In some embodiments, the method involves administering a composition comprising a cyclosporine analog of formula L, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, to a subject in need, thereby reducing the formation of blood clots in the subject:
[0004] [ka] (In the formula: a. R' is either H or acetyl; b.R1 is a saturated or unsaturated linear or branched aliphatic carbon chain of 2 to 15 carbon atoms; c.R2 is selected from the following group: iH; ii. Unsubstituted, N-substituted, or N,N disubstituted amides; iii. N-substituted or unsubstituted acyl-protected amines; iv. N-substituted or unsubstituted amines; v. Carboxylic acid; vi.nitrile; vii. Esther; viii. Ketones; ix. Hydroxy, dihydroxy, trihydroxy or polyhydroxyalkyl; and x. Substitutable or non-substitutable aryl; xi. A saturated or unsaturated linear or branched aliphatic chain optionally containing substituents selected from the group consisting of hydrogen, ketones, hydroxyl, nitrile, carboxylic acid, ester, 1,3-dioxolane, halogen, and oxo; xii. Aromatic groups containing substituents selected from the group consisting of halogens, esters, and nitros; and xiii. A combination of a saturated or unsaturated linear or branched aliphatic chain of (xi) and an aromatic group of (xii); d.R23 is a selectively substituted aliphatic carbon chain, either saturated or unsaturated, linear or branched.
[0005] In some embodiments, the cyclosporine analog of formula L is CRV431. [ka] (CRV431)
[0006] In some embodiments, the composition comprises a therapeutic or prophylactic effective amount of a cyclosporine analog (e.g., CRV431). Thromboembolic disorders may be, for example, arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, or ventricular or peripheral circulatory thromboembolic disorders. In some embodiments, thromboembolic disorders may be unstable angina, acute coronary syndrome, myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary thrombosis, cerebral artery thrombosis, cerebral embolism, renal embolism, pulmonary embolism, or thrombosis resulting from a medical graft, device or procedure in which blood is exposed to an artificial surface that promotes thrombosis. In some embodiments, thromboembolic disorders include thrombosis induced by stroke, myocardial infarction, unstable anguina, abrupt closure following angioplasty or stent placement, peripheral vascular surgery or peripheral vascular disease, or thrombotic disorders resulting from atrial fibrillation or inflammation.
[0007] In some embodiments, the method includes reducing thrombus formation in a subject by at least 5%, 10%, 20%, 50%, 70%, 90%, or more. In some embodiments, the method includes delaying or reducing the likelihood of thrombus formation in a subject. For example, the method can delay the likelihood of thrombus formation in a subject by 1 minute, 2 minutes, 3 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, or more, or by at least 1 minute, 2 minutes, 3 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, or more, or within a range of any of these values. In some embodiments, the method reduces the likelihood of thrombus formation in a subject by 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or more, or by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or more, or within a range of any two of these values. In some embodiments, the method includes preventing or delaying the initiation of thrombus formation in a subject. For example, the method can delay the onset of thrombus formation in a subject by 1 minute, 2 minutes, 3 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours or more, or by at least 1 minute, 2 minutes, 3 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours or more, or within a range of any of these values. In some embodiments, the method includes reducing the risk of bleeding in a subject by at least 5%, 10%, 20%, 50%, 70%, 90%, or more. In some embodiments, platelet aggregation in the subject is not inhibited. In some embodiments, platelet aggregation in the subject is reduced by 80% or less, 70%, 60%, 50%, 40%, 30%, 20%, 10%, or 5% compared to an untreated subject. In some embodiments, the cyclosporine analog selectively inhibits the formation of progenitor platelets. In some embodiments, the method includes selectively inhibiting the formation of progenitor platelets. In some embodiments, the method reduces thrombus formation without inhibiting platelet aggregation.In some embodiments, this method does not inhibit platelet aggregation.
[0008] In some embodiments, the subjects requiring it are those suffering from or at risk of developing a prothrombus-forming or thrombotic condition. Non-limiting examples of prothrombus-forming and thrombotic conditions include infections, sepsis, systemic inflammatory response syndromes, multiple organ failure, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, angiogenesis, renal failure, ischemic rebound injury, parenchymal organ transplant rejection, cardiovascular disease, stroke, venous thromboembolism, autoimmune disorders, sickle cell disease, inflammatory bowel disease, acute lung injury, malignant tumors, myocardial infarction (primary and secondary), embolic stroke, ischemic stroke, thrombotic stroke, deep vein thrombosis (DVT), thromboembolism, portal vein thrombosis, renal vein thrombosis, jugular vein thrombosis, Budd-Chiari syndrome, Paget-Schröder syndrome, cerebral venous sinus thrombosis, arterial thrombosis, and arterial embolism.
[0009] In some embodiments, the composition comprises a therapeutic or prophylactic effective dose of a cyclosporine analog (e.g., CRV431). In some embodiments, the subject is a mammal, such as a human. The human may be, for example, an elderly person (e.g., at least 60 years of age) or a minor (e.g., 18 years of age or younger). In some embodiments, the composition comprises one or more pharmaceutically acceptable excipients. In some embodiments, the composition comprises one or more additional therapeutic agents. In some embodiments, the method further comprises administering one or more additional therapeutic agents to a subject in need thereof. One or more additional therapeutic agents may include, for example, anticoagulants, antiplatelet agents, fibrinolytic agents, or a combination thereof. Non-limiting examples of additional therapeutic agents include heparin, low molecular weight heparin, bivalirudin, fondaparinux, warfarin, asenocumarol, fenprocumone, phenindione, avokinase (urokinase), streptokinase, alteplase, retaplase, tenecteplase, prasugrel, aspirin, ticlopidine, clopidogrel, absiximab, eptifivatide, tirofiban, or combinations thereof. In some embodiments, at least one of one or more additional therapeutic agents is administered to the subject concurrently with the composition. In some embodiments, at least one of one or more additional therapeutic agents is administered to the subject before, after, or both, the composition. In some embodiments, the composition is administered to the subject by intravenous, oral, or parenteral administration, for example, by oral or intravenous administration. In some embodiments, the composition is in the form of a powder, pill, tablet, microtablet, pellet, micropellet, capsule, capsule containing a microtablet, liquid, aerosol, or nanoparticles. In some embodiments, the composition is administered to a subject in an effective daily dose of 10 mg to 250 mg of a cyclosporine analog or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
[0010] Further disclosed herein are kits comprising a cyclosporine analog of formula L, or a pharmaceutically acceptable salt, solvate, stereoisomer, or composition thereof, and a label indicating the use of the kit. In some embodiments, the label indicates that the kit is for preventing or treating thromboembolic disorders. In some embodiments, the label indicates that the kit is for preventing or reducing thrombus formation. In some embodiments, the label indicates that the kit is for reducing or inhibiting protozoal platelet formation. In some embodiments, the kit includes a label indicating that the kit is for preventing or treating thromboembolic disorders. In some embodiments, the kit includes a label indicating that the kit is for reducing or inhibiting protozoal platelet formation.
[0011] In some embodiments, thromboembolic disorders are arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, or thromboembolic disorders in the ventricles or peripheral circulation. Thromboembolic disorders may include unstable angina, acute coronary syndrome, myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary thrombosis, cerebral artery thrombosis, cerebral embolism, renal embolism, pulmonary embolism, or thrombosis resulting from medical grafts, devices or procedures that expose blood to artificial surfaces that promote thrombosis. Thromboembolic disorders may also include thrombosis induced by stroke, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, peripheral vascular surgery or peripheral vascular disease, or thrombotic disorders resulting from atrial fibrillation or inflammation.
[0012] In some embodiments, subjects have or are at risk of developing a prothrombus-forming or thrombotic condition. Prothrombus-forming or thrombotic conditions can be selected from the group consisting of infection, sepsis, systemic inflammatory response syndrome, multiple organ failure, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, angiogenesis, renal failure, ischemic rebound injury, parenchymal organ transplant rejection, cardiovascular disease, stroke, venous thromboembolism, autoimmune disorders, sickle cell disease, inflammatory bowel disease, acute lung injury, malignant tumors, myocardial infarction (primary and secondary), embolic stroke, ischemic stroke, thrombotic stroke, deep vein thrombosis (DVT), thromboembolism, portal vein thrombosis, renal vein thrombosis, jugular vein thrombosis, Budd-Chiari syndrome, Paget-Schröder syndrome, cerebral venous sinus thrombosis, arterial thrombosis, and arterial embolism. In some embodiments, the cyclosporine analog is CRV431. In some embodiments, the labeling includes instructions for administering a therapeutic or prophylactic effective dose of the cyclosporine analog. In some embodiments, the subject is a mammal such as a human. In some embodiments, the cyclosporine composition comprises one or more pharmaceutically acceptable excipients.
[0013] In some embodiments, the labeling includes instructions to administer the cyclosporine analog together with one or more additional therapeutic agents. The kit may further include one or more of the one or more additional therapeutic agents. The one or more additional therapeutic agents may include anticoagulants, antiplatelet agents, fibrinolytic agents, or combinations thereof. The one or more additional therapeutic agents may include heparin, low molecular weight heparin, bivalirudin, fondaparinux, warfarin, asenocumarol, fenprocumone, phenindione, avokinase (urokinase), streptokinase, alteplase, retaplase, tenecteplase, prasugrel, aspirin, ticlopidine, clopidogrel, absiximab, eptifivatide, tyrofiban, or combinations thereof. In some embodiments, the instructions include instructions to administer at least one of the one or more additional therapeutic agents together with the cyclosporine analog to the subject. In some embodiments, the instructions include administering to the subject at least one of one or more additional therapeutic agents before administration of the cyclosporine analog to the subject, after administration of the cyclosporine analog to the subject, or both.
[0014] In some embodiments, instructions include administering the cyclosporine analog to a subject by intravenous, oral, or parenteral administration. Instructions may include administering the cyclosporine analog to a subject by oral or intravenous administration. In some embodiments, instructions include administering the cyclosporine analog to a subject in an effective daily dose of 10 mg to 250 mg of the cyclosporine analog or its pharmaceutically acceptable salt, solvate, or stereoisomer. In some embodiments, the cyclosporine analog is in the form of a powder, pill, tablet, microtablet, pellet, micropellet, capsule, capsule containing a microtablet, liquid, stable self-microemulsifying drug delivery system (SMEDD), aerosol, or nanoparticles.
[0015] Disclosed herein are pharmaceutical compositions comprising a cyclosporine analog of formula L, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, for use in treating thrombotic disorders; pharmaceutical compositions comprising a cyclosporine analog of formula L or a pharmaceutically acceptable salt, solvate or stereoisomer thereof for use in preventing or reducing thrombus formation; and pharmaceutical compositions comprising a cyclosporine analog of formula L, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof for use in reducing or inhibiting prothrombin platelet formation. The pharmaceutical compositions may be for administration to a subject, such as a mammal, e.g., a human. In some embodiments, the cyclosporine analog is CRV431.
[0016]
Chemical formula
[0017] In some embodiments, thromboembolic disorders are arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, or thromboembolic disorders in the ventricles or peripheral circulation. In some embodiments, thromboembolic disorders are unstable angina, acute coronary syndrome, myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary thrombosis, cerebral artery thrombosis, cerebral embolism, renal embolism, pulmonary embolism, or thrombosis resulting from medical grafts, devices or procedures in which blood is exposed to an artificial surface that promotes thrombosis. In some embodiments, thromboembolic disorders are stroke, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, peripheral vascular surgery or peripheral vascular disease, or thrombotic disorders resulting from atrial fibrillation or inflammation.
[0018] In some embodiments, subjects have or are at risk of developing a prothrombus-forming or thrombotic condition. Prothrombus-forming or thrombotic conditions can be selected from the group consisting of infection, sepsis, systemic inflammatory response syndrome, multiple organ failure, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, angiogenesis, renal failure, ischemic rebound injury, parenchymal organ transplant rejection, cardiovascular disease, stroke, venous thromboembolism, autoimmune disorders, sickle cell disease, inflammatory bowel disease, acute lung injury, malignant tumors, myocardial infarction (primary and secondary), embolic stroke, ischemic stroke, thrombotic stroke, deep vein thrombosis (DVT), thromboembolism, portal vein thrombosis, renal vein thrombosis, jugular vein thrombosis, Budd-Chiari syndrome, Paget-Schröder syndrome, cerebral venous sinus thrombosis, arterial thrombosis, and arterial embolism.
[0019] In some embodiments, the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical composition is intended for administration with one or more additional therapeutic agents. The pharmaceutical composition may further comprise one or more of the one or more additional therapeutic agents. One or more additional therapeutic agents may include anticoagulants, antiplatelet agents, fibrinolytic agents, or combinations thereof. One or more additional therapeutic agents may include heparin, low molecular weight heparin, bivalirudin, fondaparinux, warfarin, asenocumarol, fenprocumone, phenindione, avokinase (urokinase), streptokinase, alteplase, retaplase, tenecteplase, prasugrel, aspirin, ticlopidine, clopidogrel, absiximab, eptifivatide, tyrofiban, or combinations thereof.
[0020] In some embodiments, at least one of one or more additional therapeutic agents is for co-administration with a cyclosporine analog to the subject. In some embodiments, at least one of one or more additional therapeutic agents is for administration to the subject before, after, or both of the pharmaceutical composition to the subject. In some embodiments, the pharmaceutical composition is formulated for intravenous, oral, or parenteral administration. The pharmaceutical composition can be formulated for oral or intravenous administration. In some embodiments, the pharmaceutical composition is for administration to the subject at an effective daily dose of cyclosporine analog or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, in doses ranging from 10 mg to 250 mg. In some embodiments, the pharmaceutical composition is in the form of a powder, pill, tablet, microtablet, pellet, micropellet, capsule, capsule containing a microtablet, liquid, stable self-microemulsifying drug delivery system (SMEDD), aerosol, or nanoparticles.
[0021] Disclosed herein are embodiments of the use of pharmaceutical compositions comprising a cyclosporine analog of formula L or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof for the manufacture of a pharmacopoeia for treating thromboembolic disorders, preventing or reducing thrombus formation, or reducing or inhibiting protozoal platelet formation in a subject.
[0022] [ka] (In the formula: a. R' is either H or acetyl; b.R1 is a saturated or unsaturated linear or branched aliphatic carbon chain of 2 to 15 carbon atoms; c.R2 is selected from the following group: iH; ii. Unsubstituted, N-substituted, or N,N disubstituted amides; iii. N-substituted or unsubstituted acyl-protected amines; iv. N-substituted or unsubstituted amines; v. Carboxylic acid; vi.nitrile; vii. Esther; viii. Ketones; ix. Hydroxy, dihydroxy, trihydroxy or polyhydroxyalkyl; and x. Substitutable or non-substitutable aryl; xi. A saturated or unsaturated linear or branched aliphatic chain optionally containing substituents selected from the group consisting of hydrogen, ketones, hydroxyl, nitrile, carboxylic acid, ester, 1,3-dioxolane, halogen, and oxo; xii. Aromatic groups containing substituents selected from the group consisting of halogens, esters, and nitros; and xiii. A combination of a saturated or unsaturated linear or branched aliphatic chain of (xi) and an aromatic group of (xii); d.R23 is a selectively substituted aliphatic carbon chain, either saturated or unsaturated, linear or branched. [Brief explanation of the drawing]
[0023] [Figure 1A] This figure shows typical platelet aggregation traces and responses to increasing concentrations of CRV431. Aggregation was induced by collagen (1 μg / ml). [Figure 1B] This figure shows summarized platelet aggregation measurement data from N=10 independent experiments. P>0.05. [Figure 2A] This figure shows typical platelet aggregation traces and responses to increasing concentrations of CRV431. Aggregation was induced by thrombin (0.1 U / ml). [Figure 2B] This figure shows summarized platelet aggregation measurement data from N=9 independent experiments. P>0.05. [Figure 3A-B] This figure shows platelet aggregation traces from a single blood donor, demonstrating that CRV431 at the highest concentration tested does not inhibit platelet aggregation (Figure 3A), but platelet aggregation is inhibited by acetylsalicylic acid (ASA) (Figure 3B). [Figure 4A] This figure shows a typical flow cytometry histogram, demonstrating that the increasing concentration of CRV431 reduces the percentage of phosphatidylserine (PS)-positive platelets induced by collagen (10 μg / ml) and thrombin (0.1 U / ml). [Figure 4B] This figure shows summarized flow cytometry data from N=8 independent experiments. **, P<0.01 vs. vehicle control; ***, P<0.001 vs. vehicle control. [Figure 5A-B] This figure shows data on platelet PS exposure in the presence of 1 μg / ml collagen and 0.1 U / ml thrombin (Figure 5A) and 10 μg / ml collagen and 0.1 U / ml thrombin (Figure 5B). [Modes for carrying out the invention]
[0024] Throughout the drawings, reference numbers may be reused to indicate correspondences between referenced elements. The drawings are provided to illustrate exemplary embodiments described herein and are not intended to limit the scope of this disclosure.
[0025] In the following detailed description, references are made to the accompanying drawings which form part of this specification. In the drawings, similar symbols typically identify similar components unless the context indicates otherwise. The exemplary embodiments described in the detailed description, drawings and claims are not intended to be limiting. Other embodiments may be used, and other modifications may be made without departing from the spirit or scope of the subject matter represented herein. It will be readily understood that the aspects of this disclosure can be arranged, substituted, combined, separated and designed in a wide variety of different configurations, as generally described herein and illustrated in the drawings, all of which are expressly intended herein and form part of this disclosure herein. All patents, published patent applications, other publications, and sequences from GenBank, and other databases referred to herein, are incorporated in their entirety by reference with respect to the relevant scientific and technological matters.
[0026] definition Unless otherwise defined, the technical and chemical terms used herein have the same meanings as commonly understood by those skilled in the art to which this disclosure belongs. See, for example, Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, NY 1994); Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press (Cold Spring Harbor, NY 1989). For the purposes of this disclosure, the following terms are defined below. As used herein, “subject” means the animal that is the subject of treatment, observation or experimentation. “Animal” includes cold-blooded and warm-blooded vertebrates and invertebrates, such as fish, mollusks, reptiles, and especially mammals. “Mammal” includes, without limitation, mice; rats; rabbits; guinea pigs; dogs; cats; sheep; goats; cattle; horses; primates, such as monkeys, chimpanzees, and apes, and especially humans.
[0027] As used herein, “patient” means a subject treated by a medical professional, such as a physician (i.e., an allopathic or osteopathic physician) or a veterinary physician, in an attempt to cure or at least alleviate the effects of a particular disease or disorder, or to prevent the disease or disorder from occurring at a first location. As used herein, “administer” or “to administer” refers to a method of delivering a pharmacoactive ingredient in a given dose to a vertebrate. As used herein, “dosage” refers to the combined amount of the active ingredient (e.g., cyclosporine analogs including CRV431). As used herein, “unit dose” refers to the amount of therapeutic agent administered to a patient in a single dose. As used herein, “daily dose” refers to the total amount of therapeutic agent administered to a patient in a day. As used herein, “therapeutic dose” or “pharmaceutical dose” means the amount of a therapeutic agent that has a therapeutic effect. The therapeutic dose is the amount of a pharmacoactive component that is useful in treatment when administered alone or in combination with one or more additional therapeutic agents. Therefore, as used herein, the therapeutic dose means the amount of a therapeutic agent that produces the desired therapeutic effect as determined by clinical trial results and / or model animal studies.
[0028] As used herein, the terms “to treat,” “treatment,” or “to treat” refer to administering a therapeutic agent or pharmaceutical composition to a subject for preventive and / or therapeutic purposes. The term “preventive treatment” refers to treating a subject who is not yet exhibiting symptoms of a disease or condition but is susceptible to or otherwise at risk of a particular disease or condition, thereby reducing the likelihood that the patient will develop the disease or condition. The term “therapeutic treatment” refers to administering a treatment to a subject who is already suffering from a disease or condition. As used herein, “therapeutic effect” refers to alleviating, to some extent, one or more symptoms of a disease or disorder. For example, a therapeutic effect can be observed by a reduction in subjective discomfort reported by the subject (e.g., a reduction in discomfort described in a self-administered patient questionnaire). As used herein, the terms “prevention” or “prevention” refer to preventive measures for asymptomatic disease conditions in subjects, e.g., mammals (including humans), to reduce the probability of the development of a clinical disease condition. Subjects are selected for preventive treatment based on factors known to increase the risk of developing a clinical disease condition compared to the general population. “Preventive” treatment can be divided into (a) primary prevention and (b) secondary prevention. Primary prevention is defined as measures taken in subjects that do not yet exhibit a clinical disease condition, while secondary prevention is defined as preventing a second development of the same or similar clinical disease condition. As used herein, the term “thrombosis” refers to the formation or presence of a thrombus (singular) or thrombus(plural); a blood clot in a blood vessel that can cause ischemia or infarction of tissue supplied by the vessel. The term “embolism” refers to the sudden blockage of an artery by a blood clot or foreign material carried by the bloodstream to its origin site. The term “thromboembolism” refers to the occlusion of a blood vessel by thrombotic material carried by the bloodstream from its origin site to block another blood vessel. The term “thromboembolic disorder” encompasses both “thrombotic” and “embolic” disorders.
[0029] As used herein, the terms “thromboembolic disorder” and “thrombotic disorder” are interchangeable and include, but are not limited to, arterial cardiovascular thromboembolic disorders, venous cardiovascular or cerebrovascular thromboembolic disorders, and thromboembolic disorders in the ventricles or peripheral circulation. The terms “thromboembolic disorder” and “thrombotic disorder” also include, but are not limited to, certain disorders selected from, unstable angina or other acute coronary syndromes, atrial fibrillation, first or recurrent myocardial infarction, sudden ischemic death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary thrombosis, cerebral artery thrombosis, cerebral embolism, renal embolism, pulmonary embolism, and thrombosis resulting from medical grafts, devices or procedures in which blood is exposed to an artificial surface that promotes thrombosis. Medical grafts or devices include, but are not limited to, prosthetic valves, artificial valves, indwelling catheters, stents, blood oxygenation devices, shunts, vascular access ports, circulatory support devices, and artificial hearts or ventricles, as well as vascular grafts. Procedures include, but are not limited to, cardiopulmonary bypass, percutaneous coronary intervention, and hemodialysis. In some embodiments, the term “thromboembolic disorder” includes acute coronary syndrome, stroke, deep vein thrombosis, and pulmonary embolism. As used herein, the term “stroke” refers to an embolic stroke or atherothrombotic stroke resulting from occlusive thrombosis in the common carotid artery, carotid intima, or intracerebral arteries.
[0030] thrombosis Hemostasis is a physiological response to vascular injury in relation to control blood loss. Vascular injury triggers rapid activation and aggregation of platelets in the primary hemostatic process, resulting in an unstable platelet plug. Secondary hemostasis involves the activation of plasma-derived coagulation factors, which is necessary to form a fibrin reticular structure to stabilize the platelet plug. Thrombosis occurs when this process occurs excessively or in the wrong location. Thrombosis can occur in the arterial or venous system and can lead to clinical outcomes including myocardial infarction, stroke, and deep vein thrombosis. In thrombosis, a blood clot or thrombus may form, locally obstructing circulation and causing ischemia and organ damage. Alternatively, in a process known as embolism, the clot migrates and subsequently becomes trapped in a distal vessel, where it again causes ischemia and organ damage. Diseases resulting from pathological thrombus formation are collectively referred to as thromboembolic disorders (or thrombotic disorders) and include, but are not limited to, acute coronary syndrome, unstable angina, myocardial infarction, thrombosis in cardiac cavities, ischemic stroke, deep vein thrombosis, peripheral occlusive arterial disease, transient ischemic attack, and pulmonary embolism. Thrombosis can also occur on artificial surfaces in contact with blood, including catheters, stents, artificial heart valves, and hemodialysis membranes. Exemplary conditions that contribute to the risk of developing thrombosis include alterations in the vascular wall, changes in blood flow, and alterations in the composition of vascular compartments.
[0031] Activated platelets play a dual role in hemostasis and thrombosis. They aggregate to form platelet plugs and, moreover, provide a surface for the aggregation of coagulation factors. A subset of activated platelets called “coagulant platelets” has different properties, including the ability to support thrombin production. Patients with higher levels of coagulant platelets following aortic stroke have been found to have a higher risk of stroke recurrence. In patients with sepsis, platelet mitochondrial membrane depolarization, a preliminary requirement for the formation of platelet coagulant subsets, correlated with disease severity and disease outcome. The antithrombotic agents disclosed herein can prevent the formation of coagulant platelets in some embodiments, but do not inhibit platelet aggregation. In some embodiments, antithrombotic agents are administered to subjects requiring treatment of arterial or venous thrombosis, including those associated with coronary artery disease, stroke, venous thromboembolism, autoimmune vasculitis, and sepsis.
[0032] A variety of assays are currently used to determine the efficacy of antithrombotic agents, including, but not limited to, in vitro enzyme assays, in vitro coagulation and clotting assays, and in vivo models of thrombosis. Assays for determining the efficacy of anticoagulant therapy include activity assays for components of coagulation signaling pathways (e.g., factor XIIa and thrombin), and coagulation assays. Assays for determining the efficacy of antiplatelet therapy include several platelet activation and adhesion assays. Flow cytometry is also often used to determine platelet activation. In vivo assays can be common to all drug classes, as the common goal is to prevent and / or treat thrombus formation. Several models exist for these, which are also included below. These risk factors are collectively known as the Virchow triad.
[0033] The antithrombotic effects of the antithrombotic agents disclosed herein can be determined and measured using any known method for determining and / or measuring antithrombotic activity (including in vitro, ex vivo, and in vivo methods / assays). For example, the effects of antithrombotic agents as inhibitors of coagulation factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein, or thrombin can be determined using methods known in the art, such as in vitro methods using the relevant purified serine protease and appropriate synthetic substrates, respectively. The rate of hydrolysis of the chromogenic or fluorescent substrate by the relevant serine protease can be measured in the absence and presence of the antithrombotic agent. In some embodiments, the hydrolysis of the substrate resulted in the release of pNA (p-nitroaniline), which is spectrophotometrically monitored by measuring the increase in absorbance at 405 nm, or the release of AMC (aminomethylcoumarin), which is spectrofluorescently monitored by measuring the increase in emission at 460 nm with excitation at 380 nm. A decrease in the rate of absorbance or fluorescence change in the presence of an inhibitor indicates enzyme inhibition. The results of this assay are expressed as an inhibition constant, Ki. The antithrombotic agents disclosed herein may be inhibitors for one or more coagulation factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein, and thrombin. In some embodiments, the antithrombotic agent is an inhibitor for all of the coagulation factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein, and thrombin. In some embodiments, the antithrombotic agent is not an inhibitor for at least one of the coagulation factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein, and thrombin. In some embodiments, the antithrombotic agent is not an inhibitor for at least two or more of the coagulation factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein, and thrombin.
[0034] In some embodiments, the effect of the antithrombotic agents disclosed herein as coagulation inhibitors is determined using standard or modified coagulation assays. For example, an increase in plasma coagulation time in the presence of an inhibitor indicates anticoagulation. The relative coagulation time is the coagulation time in the presence of the inhibitor divided by the coagulation time in the absence of the inhibitor. The results of this assay can be expressed as the inhibitor concentration required to increase the coagulation time by 1.5 hours or 2 hours, respectively, relative to the coagulation time in the absence of the inhibitor, IC1.5× or IC2×. IC1.5× or IC2× is found by linear interpolation from a relative coagulation time versus inhibitor concentration plot using inhibitor concentrations reaching IC1.5× or IC2×. Coagulation time is determined using citrated normal human plasma, as well as plasma obtained from animals such as rats or rabbits. Plasma coagulation assays can be performed using automated coagulation analyzers (Sysmex, Dade-Behring, Ill.). Similarly, coagulation time can be determined from animals or humans administered with antithrombotic agents.
[0035] The antithrombotic agents disclosed herein can be tested in vitro, ex vivo, and in vivo for their ability to inhibit platelet aggregation, including gamma-thrombin-induced platelet aggregation. For example, platelet aggregation can be monitored in a 96-well microplate aggregation assay format or using a standard platelet aggregation analyzer. In some embodiments, the antithrombotic agent is tested using an alpha-thrombin-induced platelet aggregation assay or a tissue factor-induced platelet aggregation assay. In some embodiments, the antithrombotic agent inhibits platelet aggregation. In some embodiments, the antithrombotic agent does not inhibit platelet aggregation. In some embodiments, the antithrombotic agent reduces platelet aggregation. The antithrombotic effects of the antithrombotic agents disclosed herein can be determined using relevant in vivo thrombosis models, including, but not limited to, in vivo electro-induced carotid thrombosis models, FeCl3-induced carotid thrombosis models, and arteriovenous shunt thrombosis models. For example, the rabbit ECAT model described by Wong et al. (J. Pharmacol. Exp. Ther., 295:212-218 (2000)) and the rabbit AV shunt model described by Wong et al. (Wong, PC et al., J. Pharmacol. Exp. Ther. 292:351-357 (2000)) may be used.
[0036] Prevention and treatment methods Disclosed herein are methods for treating thromboembolic disorders and methods for preventing thromboembolic disorders (including primary and secondary prevention). The methods of this disclosure can be used in some embodiments to reduce or prevent thrombus formation. These methods can also be used to reduce or inhibit platelet formation.
[0037] In some embodiments, the method includes: administering a composition (e.g., SMEDD) containing a cyclosporine analog (e.g., CRV431) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof to a subject in need, where the subject in need is a subject at risk of or suffering from a thromboembolic disorder. In some embodiments, thrombus formation is prevented from occurring. In some embodiments, thrombus formation is reduced. For example, thrombus formation is reduced by at least 5%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, or by at least about 5%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more. In some embodiments, the likelihood of thrombus formation is delayed or reduced. For example, the likelihood of thrombus formation is reduced or delayed by at least 5%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, or by at least about 5%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more. In some embodiments, the onset of thrombus formation is delayed. The delay may be, for example, a few seconds, a few minutes, a few hours, a few days, a few weeks, or a few months. In some embodiments, the onset of thrombus formation is delayed by at least 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes or more, or by at least about 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes or more. In some embodiments, the onset of thrombus formation is delayed by at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours or more, or by at least about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours or more.
[0038] The antithrombotic agents disclosed herein can be used for the primary and secondary prevention (i.e., prevention or risk reduction) of thromboembolic disorders, as well as for the treatment of existing thrombotic processes. For example, the antithrombotic agents can be administered to patients at risk of developing thromboembolic disease due to the presence of one or more predisposing risk factors from the Virchow triad to prevent the formation of occlusive thrombi (primary prevention). For example, in orthopedic surgical settings (e.g., hip and knee replacement), the antithrombotic agents can be administered before the surgical procedure. The antithrombotic agents can balance the pro-thrombus-forming stimuli exerted by changes in blood composition due to altered vascular flow (stagnation), potential surgical damage to the blood vessel wall, and acute responses associated with surgery. The antithrombotic agents can also be used in patients at risk of developing thrombotic cardiovascular disease. The antithrombotic agents disclosed herein may also be used in secondary prevention following an initial thrombotic episode. For example, patients with mutations in factor V (also known as factor V Leiden) and additional risk factors (e.g., pregnancy) may be administered antithrombotic agents to prevent recurrence of venous thrombosis. In some embodiments, antithrombotic agents are used in secondary prevention of cardiovascular events in patients with a history of acute myocardial infarction or acute coronary syndrome.
[0039] The antithrombotic agents disclosed herein are, in some embodiments, administered to subjects who require treatment of a disease state after it has already begun (i.e., by stopping its progression). For example, patients with deep vein thrombosis are treated with antithrombotic agents to prevent further progression of venous occlusion. In some embodiments, over time, antithrombotic agents can induce regression of the disease state because the balance between thrombus-forming factors and anticoagulant / fibrinolytic pathways is altered in favor of the latter. An example relating to the arterial vascular bed is the treatment of patients with acute myocardial infarction or acute coronary syndrome using aspirin and clopidogrel to prevent further progression of vascular occlusion, ultimately leading to regression of the thrombotic occlusion. The antithrombotic agents disclosed herein are administered to subjects in which it is necessary to prevent or reduce "contact activation" of coagulation that occurs when blood is exposed to an artificial surface (e.g., during hemodialysis, "on-pump" cardiovascular surgery, vascular grafting, bacterial sepsis) on the cell surface, cell receptors, cell debris, DNA, RNA, and extracellular matrix, in some embodiments.
[0040] Thrombosis may include, but is not limited to, vascular occlusion (e.g., after bypass) and reocclusion (e.g., during or after percutaneous coronary intervention). Thromboembolic disorders may result from conditions such as atherosclerosis, surgery or surgical complications, prolonged fixation, arterial fibrillation, congenital thrombotic predisposition, cancer, diabetes, the effects of drug therapy or hormones, and complications of pregnancy. In some embodiments, thromboembolic disorders are associated with patients with atherosclerosis. In some embodiments, arterial fibrillation and subsequent thromboembolic disorders include cardiovascular diseases, rheumatic heart disease, non-rheumatic mitral valve disease, hypertensive cardiovascular disease, chronic lung disease, cardiac abnormalities, and thyroid toxicity. In some embodiments, thromboembolic disorders are associated with diabetes mellitus. In some embodiments, thromboembolic disorders are associated with a congenital thrombotic predisposition that may be caused by or related to the loss of gain-of-function mutations in coagulation factors or functional mutations in the anticoagulant or fibrinolytic pathways. Thrombosis may be associated with one or more tumor types, such as pancreatic cancer, breast cancer, brain tumors, lung cancer, ovarian cancer, prostate cancer, gastrointestinal malignancies, and Hodgkin or non-Hodgkin lymphoma. In some embodiments, thrombosis is associated with prostate cancer, colorectal cancer, brain cancer, lung cancer, breast cancer, ovarian cancer, or a combination thereof. In some embodiments, the thromboembolic disorder is venous thromboembolism (VTE) in cancer patients. The risk of thrombosis in cancer patients may vary for one or more of the following: (i) the stage of cancer (i.e., the presence of metastases), (ii) the presence of a central venous catheter, (iii) anti-cancer treatment including surgery and chemotherapy, and (iv) hormones and anti-angiogenic drugs. In some embodiments, one or more of the disclosed antithrombotic agents are administered to patients with advanced tumors to prevent thromboembolic disorders. In some embodiments, the antithrombotic agent is administered to cancer patients who are bedridden for a long period of time, outpatients receiving chemotherapy or radiation therapy, cancer patients with an indwelling central venous catheter, or cancer patients undergoing surgery.
[0041] As described herein, cyclosporine analogs (e.g., CRV431) can be used to treat or prevent thromboembolic disorders (e.g., as primary or secondary prevention). In some embodiments, cyclosporine analogs can prevent thromboembolic disorders (or reduce or prevent thrombus formation, or reduce or inhibit platelet aggregation) without causing or increasing the risk of bleeding in the target population. Cyclosporine analogs can also be used to reduce or prevent thrombus formation. Cyclosporine analogs can also be used to reduce or inhibit platelet aggregation. In some embodiments, cyclosporine analogs can prevent or treat thromboembolic disorders without inhibiting platelet aggregation. In some embodiments, cyclosporine analogs can prevent or treat thromboembolic disorders without completely inhibiting platelet aggregation (for example, platelet aggregation is reduced by approximately 85%, 80%, 70%, 60%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or less in the subjects compared to the untreated subjects, or by at most approximately 85%, 80%, 70%, 60%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or less in the subjects). In some embodiments, cyclosporine analogs can reduce the risk of bleeding (for example, by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more compared to untreated subjects).In some embodiments, cyclosporine analogs can reduce thrombus formation, delay or reduce the likelihood of thrombus formation, prevent or delay the initiation of thrombus formation, and / or reduce the risk of bleeding without inhibiting (or by selective inhibition of) progenitor platelet formation and / or without inhibiting platelet aggregation (or by reducing or partially inhibiting platelet aggregation, for example, by reducing platelet aggregation by 85%, 80%, 70%, 60%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5% or less in a subject compared to an untreated subject, or at most 85%, 80%, 70%, 60%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5% or less in a subject).
[0042] hindrance In some embodiments, cyclosporine analogs are used to treat or prevent thromboembolic disorders in a subject. For example, thromboembolic disorders may be arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, or thromboembolic disorders in the ventricles or peripheral circulation. Thromboembolic disorders may include, for example, unstable angina, acute coronary syndrome, myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary thrombosis, cerebral artery thrombosis, cerebral embolism, renal embolism, pulmonary embolism, or thrombosis resulting from medical grafts, devices or procedures in which blood is exposed to an artificial surface that promotes thrombosis. Another example of thromboembolic disorders is thrombosis induced by stroke, myocardial infarction, unstable anguina, abrupt closure following angioplasty or stent placement, peripheral vascular surgery or peripheral vascular disease, or thrombotic disorders resulting from atrial fibrillation or inflammation.
[0043] In some embodiments, cyclosporine analogs are used to reduce or inhibit platelet formation in subjects. Subjects have or are at risk of developing pro-thrombotic or thrombotic conditions. Thrombotic or thrombotic conditions can be selected from the group consisting of infection, sepsis, systemic inflammatory response syndrome, multiple organ failure, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, angiogenesis, renal failure, ischemic rebound injury, parenchymal organ transplant rejection, cardiovascular disease, stroke, venous thromboembolism, autoimmune disorders, sickle cell disease, inflammatory bowel disease, acute lung injury, malignant tumors, myocardial infarction (primary and secondary), embolic stroke, ischemic stroke, thrombotic stroke, deep vein thrombosis (DVT), thromboembolism, portal vein thrombosis, renal vein thrombosis, jugular vein thrombosis, Budd-Chiari syndrome, Paget-Schröder syndrome, cerebral venous sinus thrombosis, arterial thrombosis, and arterial embolism.
[0044] Therapeutic drugs Cyclosporine is also known as cyclosporine A (CsA). In some embodiments, the cyclosporine analog is a compound of formula L: [ka] (In the formula: a. R' is either H or acetyl; b.R1 is a saturated or unsaturated linear or branched aliphatic carbon chain of 2 to 15 carbon atoms; c.R2 is selected from the following group: iH; ii. Unsubstituted, N-substituted, or N,N disubstituted amides; iii. N-substituted or unsubstituted acyl-protected amines; iv. N-substituted or unsubstituted amines; v. Carboxylic acid; vi.nitrile; vii. Esther; viii. Ketones; ix. Hydroxy, dihydroxy, trihydroxy or polyhydroxyalkyl; and x. Substitutable or non-substitutable aryl; xi. A saturated or unsaturated linear or branched aliphatic chain optionally containing substituents selected from the group consisting of hydrogen, ketones, hydroxyl, nitrile, carboxylic acid, ester, 1,3-dioxolane, halogen, and oxo; xii. Aromatic groups containing substituents selected from the group consisting of halogens, esters, and nitros; and xiii. A combination of a saturated or unsaturated linear or branched aliphatic chain of (xi) and an aromatic group of (xii); d.R23 is a selectively substituted aliphatic carbon chain, either saturated or unsaturated, linear or branched.
[0045] In some embodiments, R1-R2 are selected from the group consisting of the following: [ka] In some embodiments, R1-R2 comprises a saturated or unsaturated linear or branched aliphatic chain of 2 to 5 carbon atoms, optionally substituted with substituents selected from the group consisting of hydrogen, ketones, hydroxyl, nitrile, halogen, oxo, carboxylic acid, ester, and 1,3-dioxolane.
[0046] In some embodiments, R2 is [ka] Selected from the group consisting of; R5 is a saturated or unsaturated linear or branched aliphatic carbon chain between 1 and 10 carbon atoms in length; R6 is a monohydroxylated, dihydroxylated, trihydroxylated, or polyhydroxylated linear or branched aliphatic carbon chain between 1 and 10 carbon atoms in length, either saturated or unsaturated.
[0047] In some embodiments, R23 is selected from the group consisting of: [ka] In some embodiments, R23 includes optionally substituted alkyls, including optionally substituted C1-C3 alkyls. The alkyls may be substituted with aminos and may include C1-C3-Ala, where the compound includes the D epimer of amino acid 3, to which R23 is attached. In some embodiments, R23 may be MeAla. In some embodiments, R23 is a linear or branched aliphatic carbon chain of 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 2 carbons in length.
[0048] In some embodiments, in formula L [ka] The following group is selected:
[0049] [ka]
[0050] In some embodiments, the cyclosporine analog is a compound of formula L: [ka] (In the formula: a. R' is either H or acetyl; b.R1 is a saturated or unsaturated linear or branched aliphatic carbon chain of 2 to 15 carbon atoms; c.R2 is selected from the following group: i. Unsubstituted, N-substituted, or N,N disubstituted amides; ii. Carboxylic acid; iii. Nitrile; iv. Esther; v. Ketones; vi. Hydroxy, dihydroxy, trihydroxy, or polyhydroxyalkyl; vii. Substitutable or non-substitutable aryl groups; viii. Saturated or unsaturated linear or branched aliphatic carbon chains substituted with substituents selected from the group consisting of ketones, hydroxyls, nitriles, carboxylic acids, esters, 1,3-dioxolanes, and oxos; ix. Aromatic groups substituted with substituents selected from the group consisting of halogens, esters, and nitros; and x.viii) A combination of saturated or unsaturated linear or branched aliphatic carbon chain and ix) an aromatic group; d.R23 is an unsubstituted C1-C3 alkyl group.
[0051] In some embodiments, R' is H. In some embodiments, R1 is a saturated or unsaturated linear or branched aliphatic carbon chain of 5 to 8 carbon atoms in length. In some embodiments, R2 is selected from the group consisting of: [ka] R5 is a saturated or unsaturated linear or branched aliphatic carbon chain with a length between 1 and 10 carbon atoms; R6 is a monohydroxylated, dihydroxylated, trihydroxylated, or polyhydroxylated saturated or unsaturated linear or branched aliphatic carbon chain with a length between 1 and 10 carbon atoms.
[0052] In some embodiments, R1-R2 are selected from the group consisting of the following: [ka] In some embodiments, R1-R2 are substituted with substituents selected from the group consisting of ketones, hydroxyl, nitrile, oxo, carboxylic acids, esters, and 1,3-dioxolanes. In some embodiments, R1-R2 are carbon atoms with a length of at least 6.
[0053] In some embodiments, in formula L [ka] The following group is selected: [ka]
[0054] In some embodiments, R23 is selected from the group consisting of: [ka] In some embodiments, R23 is methyl. In some embodiments, the compound comprises a D-epimer of amino acid 3, to which R23 is attached.
[0055] In some embodiments, the cyclosporine analog is a compound selected from the group consisting of: [Table 1] TIFF2023551503000018.tif248157 Here: R is
[0056] [ka] and; R' is either H or acetyl; Isomers are isomeric forms of amino acid 3, which is an amino acid to which R23 is attached.
[0057] In some embodiments, the cyclosporine analog is a compound of formula L: [ka] (In the formula: a. R' is either H or acetyl; b.R1 is a saturated or unsaturated linear or branched aliphatic carbon chain of 2 to 15 carbon atoms; c.R2 is selected from the following group: i. Unsubstituted, N-substituted, or N,N disubstituted amides; ii. Carboxylic acid; iii. Nitrile; iv. Esther; v. Ketones; vi. Hydroxy, dihydroxy, trihydroxy, or polyhydroxyalkyl; vii. Substitutable or non-substitutable aryl groups; viii. Saturated or unsaturated linear or branched aliphatic carbon chains substituted with substituents selected from the group consisting of ketones, hydroxyls, nitriles, carboxylic acids, esters, 1,3-dioxolanes, and oxos; ix. Aromatic groups substituted with substituents selected from the group consisting of halogens, esters, and nitros; and x.(viii) A combination of a saturated or unsaturated linear or branched aliphatic carbon chain and (ix) an aromatic group; d.R23 is a selectively substituted aliphatic carbon chain, which is either saturated or unsaturated, linear or branched. Here, R1-R2 are carbon atoms with a length of at least 6.
[0058] In some embodiments, R' is H. In some embodiments, R1 is a saturated or unsaturated linear or branched aliphatic carbon chain of 5 to 8 carbon atoms in length.
[0059] In some embodiments, R1-R2 are selected from the group consisting of the following: [ka] In some embodiments, R1-R2 are substituted with substituents selected from the group consisting of ketones, hydroxylomers, nitriles, oxoomers, carboxylic acids, esters, and 1,3-dioxolanes.
[0060] In some embodiments, R23 is selected from the group consisting of: [ka] In some embodiments, R23 comprises a C1-C3 alkyl group which is optionally substituted. In some embodiments, R23 is substituted with an amino acid. In some embodiments, R23 is a C1-C3 alkyl group, and the compound comprises a D-epimer of amino acid 3, to which R23 is attached. In some embodiments, R23 is methyl. In some embodiments, R23 is a linear or branched aliphatic carbon chain of 1 to 6 carbon atoms in length.
[0061] In some embodiments, in formula L [ka] The following group is selected: [ka]
[0062] In some embodiments, R1-R2 are [ka] R23 is methyl, and the compound is the D epimer of amino acid 3, to which R23 is attached.
[0063] In some embodiments, the cyclosporine analog is a compound of formula L: [ka] (In the formula: R' is either H or acetyl; R1 is a saturated or unsaturated linear or branched aliphatic carbon chain of 2 to 15 carbon atoms; R2 is an N-substituted or unsubstituted acyl-protected amine; R23 is either methyl or ethyl.
[0064] In some embodiments, R' is H. In some embodiments, R1 is a saturated or unsaturated linear or branched aliphatic carbon chain of 5 to 8 carbon atoms in length. In some embodiments, R2 is [ka] The formula is such that R5 is a saturated or unsaturated linear or branched aliphatic carbon chain of 1 to 10 carbon atoms in length.
[0065] In some embodiments, R1-R2 are selected from the group consisting of the following: [ka]
[0066] In some embodiments, R23 is methyl. In some embodiments, in formula L [ka] teeth, [ka] That is the case.
[0067] In some embodiments, R', R1-R2, and R23, as well as isomers of the compound, are selected from the following: [Table 2] Here, the isomer is an isomerized form of amino acid 3, which is the amino acid to which R23 is attached.
[0068] In some embodiments, the cyclosporine analog is a compound of formula L: [ka] (In the formula: R' is either H or acetyl; R1-R2 are selected from the following group:
[0069] [ka] R23 is a selectively substituted aliphatic carbon chain, either saturated or unsaturated, linear or branched.
[0070] In some embodiments, R' is H. In some embodiments, R1-R2 are [ka] That is the case.
[0071] In some embodiments, in formula L [ka] teeth, [ka] That is the case.
[0072] In some embodiments, R23 is selected from the group consisting of: [ka] In some embodiments, R23 is [ka] In some embodiments, R23 is
[0073] [ka] In some embodiments, R23 is (a) comprising an optionally substituted C1-C3 alkyl group; (b) substituted with an amino group; (c) C1-C3-Ala, wherein the compound comprises a D epimer; (d) MeAla; and / or (e) a linear or branched aliphatic carbon chain of 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 2 carbon atoms in length.
[0074] In some embodiments, R', R1-R2 and R23, and isomers of the compound are selected from the following: [Table 3]
[0075] In some embodiments, the cyclosporine analog is a neutral cyclic peptide consisting of 11 amino acids, a derivative or analog of cyclosporine, or a small molecule cyclophylline inhibitor CRV431 (shown below), where amino acids 1 and 3 are chemically modified.
[0076] [ka] (CRV431)
[0077] Additional treatments In some embodiments, the method may include administering one or more additional therapeutic agents to a subject in need. For example, the composition may include one or more additional therapeutic agents. Non-limiting examples of one or more additional therapeutic agents include anticoagulants, antiplatelet agents, fibrinolytic agents, or combinations thereof. In some embodiments, one or more additional therapeutic agents may include heparin, low molecular weight heparin, bivalirudin, fondaparinux, warfarin, asenocumarol, fenprocumone, phenindione, avokinase (urokinase), streptokinase, alteplase, retaplase, tenecteplase, prasugrel, aspirin, ticlopidine, clopidogrel, absiximab, eptifivatide, tyrofiban, or combinations thereof. In some embodiments, each of one or more additional therapeutic agents (or all of the additional therapeutic reagents) is administered to the subject simultaneously with the composition containing the cyclosporine analog. In some embodiments, each of one or more additional therapeutic agents (or all of the additional therapeutic reagents) is administered to the subject after administration of the composition containing the cyclosporine analog, before administration of the composition containing the cyclosporine analog, or both. The dosage and / or administration schedule of the additional therapeutic agents may be the same as or different from the dosage and / or administration schedule of the cyclosporine analog composition described herein. The route of administration of the additional therapeutic agents may be the same as or different from the route of administration of the cyclosporine analog composition described herein. The additional therapeutic agents may be administered, for example, intravenously, or orally or parenterally.
[0078] The amount of each of the one or more additional therapeutic reagents (or all of the additional therapeutic reagents) administered may be 0.1–1 mg (e.g., 0.1 mg, 0.5 mg, or 1 mg), 1–5 mg (e.g., 1 mg, 2 mg, 3 mg, 4 mg, or 5 mg), 5–10 mg (e.g., 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg), 10–20 mg (e.g., 10 mg, 15 mg, or 20 mg), or 20–30 mg (e.g., 20 mg, 25 mg, or 30 mg). It may be 30-40 mg (e.g., 30 mg, 35 mg, or 40 mg), 40-50 mg (e.g., 40 mg, 45 mg, or 50 mg), 50-100 mg (e.g., 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, or 100 mg), 100-150 mg (e.g., 100 mg, 125 mg, or 150 mg), or 150-200 mg (e.g., 150 mg, 175 mg, or 200 mg), or approximately these values. The amounts of each of the one or more additional therapeutic reagents (or all of the additional therapeutic reagents) administered are 1 mg / kg, 1.1 mg / kg, 1.2 mg / kg, 1.3 mg / kg, 1.4 mg / kg, 1.5 mg / kg, 1.6 mg / kg, 1.7 mg / kg, 1.8 mg / kg, 1.9 mg / kg, 2 mg / kg, 2.1 mg / kg, 2.2 mg / kg, 2.3 mg / kg, 2.4 mg / kg, 2.5 mg / kg, 2.6 mg / kg, 2.7 mg / kg, 2.8 mg / kg, 2.9 mg / kg, 3 mg / kg, 3.1 mg / kg, 3.2 mg / kg, 3.3 mg / kg, 3.4 mg / kg It may be kg, 3.5 mg / kg, 3.6 mg / kg, 3.7 mg / kg, 3.8 mg / kg, 3.9 mg / kg, 4 mg / kg, 4.1 mg / kg, 4.2 mg / kg, 4.3 mg / kg, 4.4 mg / kg, 4.5 mg / kg, 4.6 mg / kg, 4.7 mg / kg, 4.8 mg / kg, 4.9 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, or approximately these values, or a number or range between any two of these values.
[0079] Composition, kit and administration Some embodiments provide a kit comprising: a cyclosporine analog (e.g., CRV431), e.g., SMEDD of the cyclosporine analog, or a pharmaceutically acceptable salt, solvate, stereoisomer or composition thereof, and a label indicating the use of the kit. In some embodiments, the label indicates that the kit is for preventing thromboembolic injury. In some embodiments, the label indicates that the kit is for treating thromboembolic injury. In some embodiments, the label indicates that the kit is for reducing or inhibiting platelet formation.
[0080] In some embodiments, the label may include instructions for administering a cyclosporine analog (or a composition thereof) in the dosage, dosage schedule, and / or route of administration as described herein. For example, the label may include instructions for administering a cyclosporine analog (or a composition thereof) to a subject by intravenous, oral, or parenteral administration. The label may include instructions for administering a cyclosporine analog (or a composition thereof) to a subject by oral or intravenous administration. For example, the label may include instructions for administering a cyclosporine analog (or a composition thereof) to a subject in an effective daily dose of 10 mg to 250 mg of the cyclosporine analog or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
[0081] In some embodiments, the label includes instructions for administering the cyclosporine analog together with one or more additional therapeutic agents described herein (e.g., anticoagulants, antiplatelet agents, fibrinolytic agents, or combinations thereof). In some embodiments, the kit includes at least one of the one or more additional therapeutic agents. The label may include instructions for co-administering at least one of the one or more additional therapeutic agents to the subject together with the cyclosporine analog. The label may include instructions for administering at least one of the one or more additional therapeutic agents to the subject before administration of the cyclosporine analog to the subject, after administration of the cyclosporine analog to the subject, or both. The label may include instructions for administering one or more additional therapeutic agents in the dosages, according to the dosing schedule, and / or using the routes of administration described herein.
[0082] Provided herein, in some embodiments, is a composition comprising: a cyclosporine analog (e.g., CRV431), e.g., SMEDD of the cyclosporine analog, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, for use in treating or preventing thromboembolic disorders, for reducing or preventing thrombus formation and / or reducing or inhibiting platelet formation. The composition may include: a cyclosporine analog (e.g., CRV431), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, for use in preventing or reducing thrombus formation. The composition may include: a cyclosporine analog (e.g., CRV431), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, for use in reducing or inhibiting platelet formation. The composition may be used in combination with one or more additional therapeutic agents disclosed herein. The composition may be administered in the dosage, dosage schedule, and / or route of administration as described herein. The composition may be administered in the dosage, dosage schedule, or route of administration as disclosed herein, together with one or more additional therapeutic agents disclosed herein. The composition may contain at least one of the one or more additional therapeutic agents. Furthermore, disclosed herein is the use of a pharmaceutical composition comprising a cyclosporine analog for the manufacture of a pharmacopoeia for treating thromboembolic disorders, for preventing or reducing thrombus formation, and / or for reducing or inhibiting platelet formation.
[0083] In some embodiments, the cyclosporine analog is present in, or the composition is present in, a stable self-microemulsifying drug delivery system ("SMEDDS") formulation containing a cyclosporine derivative or analog such as CRV431. The composition enables, for example, good solubility of a cyclosporine (e.g., CRV431) derivative or analog, and enables significant blood exposure in humans. In some embodiments, the composition further comprises polyoxyl castor oil (polyoxyl 40 hydrogenated castor oil, macrogol glycerol hydroxystearate, and PEG-40 hydrogenated castor oil, e.g., also known as Cremophor® RH40 and Kolliphor® RH40). In some embodiments, the composition further comprises ethanol. In some embodiments, the composition further comprises diethylene glycol monoethyl ether (2-(2-ethoxyethoxy)ethanol, e.g., also known as Transcutol®). In some embodiments, the composition further comprises propylene glycol (PG). In some embodiments, the composition further comprises glyceryl monolinoleate, e.g., Maisine® CC. In some embodiments, the composition further comprises vitamin E. Various SMEDDS formulations of cyclosporine analogs (e.g., CRV431) are described in the PCT application published as WO2020 / 112562, the contents of which are incorporated herein by reference in their entirety.
[0084] In some embodiments, the system comprises vitamin E, Maisine® CC, propylene glycol, Transcutol®, ethanol, and Cremophor® RH40. The mass ratios of the non-cyclosporine analog components in the system may differ in different embodiments. In some embodiments, the mass ratio of a non-cyclosporine analog component (e.g., vitamin E, Maisine® CC, propylene glycol, Transcutol®, ethanol, or Cremophor® RH40) to another non-cyclosporine analog component (e.g., vitamin E, Maisine® CC, propylene glycol, Transcutol®, ethanol, or Cremophor® RH40) in the system may be between about 0.1 and about 10. In some embodiments, the mass ratio of a noncyclosporine analog component relative to another noncyclosporine analog component in the system (or relative to all other noncyclosporine analog components) may be between about 0.1 and about 10. In some embodiments, the mass ratios of non-cyclosporine analog components relative to another non-cyclosporine analog component in the system (or relative to all other non-cyclosporine components) are 0.01:1, 0.015:1, 0.02:1, 0.025:1, 0.03:1, 0.035:1, 0.04:1, 0.045:1, 0.05:1, 0.055:1, 0.06:1, 0.065:1, 0.07:1, 0.075:1, 0.08:1, 0.085:1, 0.09:1, 0.095:1, 0.1:1, 0.15:1, 0.2:1, 0.25:1, and 0.3:1. , 0.35:1, 0.4:1, 0.45:1, 0.5:1, 0.55:1, 0.6:1, 0.65:1, 0.7:1, 0.75:1, 0.8:1, 0.85:1, 0.9:1, 0.95:1, 1:1, 1.05:1, 1.1:1, 1.15:1, 1.2:1, 1.25:1, 1.3 :1, 1.35:1, 1.4:1, 1.45:1, 1.5:1, 1.55:1, 1.6:1, 1.65:1, 1.7:1, 1.75:1, 1.8:1, 1.85:1, 1.9:1, 1.95:1, 2:1, 2.05:1, 2.1:1, 2.15:1, 2.2:1, 2.25:1, 2.3:1、2.35:1、2.4:1、2.45:1、2.5:1、2.55:1、2.6:1、2.65:1、2.7:1、2.75:1、2.8:1、2.85:1、2.9:1、2.95:1、3:1、3.05:1、3.1:1、3.15:1、3.2:1、3.25:1、3.3:1、3.35:1、3.4:1、3.45:1、3.5:1、3.55:1、3.6:1、3.65:1、3.7:1、3.75:1、3.8:1、3.85:1、3.9:1、3.95:1、4:1、4.05:1、4.1:1、4.15:1、4.2:1、4.25:1、4.3:1、4.35:1、4.4:1、4.45:1、4.5:1、4.55:1、4.6:1、4.65:1、4.7:1、4.75:1、4.8:1、4.85:1、4.9:1、4.95:1、5:1、5.05:1、5.1:1、5.15:1、5.2:1、5.25:1、5.3:1、5.35:1、5.4:1、5.45:1、5.5:1、5.55:1、5.6:1、5.65:1、5.7:1、5.75:1、5.8:1、5.85:1、5.9:1、5.95:1、6:1、6.05:1、6.1:1、6.15:1、6.2:1、6.25:1、6.3:1、6.35:1、6.4:1、6.45:1、6.5:1、6.55:1、6.6:1、6.65:1、6.7:1、6.75:1、6.8:1、6.85:1、6.9:1、6.95:1、7:1、7.05:1、7.1:1、7.15:1、7.2:1、7.25:1、7.3:1、7.35:1、7.4:1、7.45:1、7.5:1、7.55:1、7.6:1、7.65:1、7.7:1、7.75:1、7.8:1、7.85:1、7.9:1、7.95:1、8:1、8.05:1、8.1:1、8.15:1、8.2:1、8.25:1、8.3:1、8.35:1、8.4:1、8.45:1、8.5:1、8.55:1、8.6:1、8.65:1、8.7:1、8.75:1、8.8:1、8.85:1、8.9:1、8.95:1、9:1、9.05:1、9.1:1、9.15:1、9.2:1、9.25:1、9.3:1、9.35:1、9.4:1、9.45:1、9.5:1、9.55:1、9.6:1、9.65:1、9.7:1、9.75:1、9.8:1、9.85:1、9.9:1、9.95:1、10:1、10.5:1, 11:1, 11.5:1, 12:1, 12.5:1, 13:1, 13.5:1, 14:1, 14.5:1, 15:1, 15.5:1, 16:1, 16.5:1, 17:1, 17.5:1, 18:1, 18.5:1, 19:1, 19.5:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36: The ratios may be 1, 37:1, 38:1, 39:1, 40:1, 41:1, 42:1, 43:1, 44:1, 45:1, 46:1, 47:1, 48:1, 49:1, 50:1, or approximately these values, at least these values, at least approximately these values, at most these values, or at most approximately these values, or a number or range between any two of these values. In some embodiments, the system contains vitamin E, Maisine® CC, propylene glycol, Transcutol®, ethanol, and Cremophor® RH40 in a mass ratio of 1 / 1 / 5 / 5 / 2.4 / 4 to 1 / 1.5 / 2.5 / 5 / 2.4 / 5. In some embodiments, the system contains vitamin E, Maisine® CC, propylene glycol, Transcutol®, ethanol, and Cremophor® RH40 in the mass ratio of (0.75-1.5) / (0.5-2) / (2-5) / (2-5) / (2-2.4) / (4-8).
[0085] In some embodiments, SMEDD contains a cyclosporine analog (e.g., CRV431) at a concentration of about 10 mg / mL to about 90 mg / mL, for example, 10 mg / mL, 20 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, a range between any two of these values, or any value within 10 mg / mL to 90 mg / mL. In some embodiments, the system contains a cyclosporine analog (e.g., CRV431) at a concentration of about 90 mg / mL. In some embodiments, the system contains a cyclosporine analog (e.g., CRV431) at a concentration of 70 mg / mL or about 70 mg / mL.
[0086] The composition is a pharmaceutical composition comprising a cyclosporine analog (e.g., CRV431), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and one or more pharmaceutically acceptable excipients. In some embodiments, the composition is administered to a subject by intravenous, nasal, pulmonary, oral, or parenteral administration. In some embodiments, the composition is in the form of a powder, pill, tablet, microtablet, pellet, micropellet, capsule, capsule containing a microtablet, stable self-microemulsifying drug delivery system ("SMEDD"), liquid, aerosol, suspension, or nanoparticles. In some embodiments, the composition is administered to a subject once, twice, or three times daily. In some embodiments, the composition is administered to a subject once or twice in an emergency situation (e.g., during ongoing surgery). In some embodiments, the composition is administered to a subject over a cycle of at least one day, at least two days, at least three days, at least one week, or longer. In some embodiments, the composition is administered to the subject in an effective daily dose of 10 mg to 250 mg of a cyclosporine analog (e.g., CRV431) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
[0087] The effective therapeutic dose and frequency of administration of cyclosporine analogs (e.g., CRV431), as well as the duration of treatment using them, can depend on various factors, including the nature and severity of the thromboembolic disorder, the potency of the cyclosporine analog (e.g., CRV431), the mode of administration, the patient's age, weight, overall health, sex, and diet, and the patient's response to treatment, and can be determined by the treating physician. In some embodiments, the therapeutically effective dose of a cyclosporine analog (e.g., CRV431) for treating or preventing thromboembolic disorders, for reducing or preventing thrombus formation, and / or reducing or inhibiting protozoal platelet formation as described herein is 0.1–200 mg, 0.1–150 mg, 0.1–100 mg, 0.1–50 mg, 0.1–30 mg, 0.5–20 mg, 0.5–10 mg, or 1–10 mg (e.g., per day or per dose), or approximately these values, or they may be administered as a single dose or in divided doses, as deemed appropriate by the treating physician. In certain embodiments, the therapeutic or prophylactic effective dose (e.g., per day or per dose) of a cyclosporine analog (e.g., CRV431) for treating or preventing thromboembolic disorders, for reducing or preventing thrombus formation, and / or for reducing or inhibiting prognathic platelet formation as described herein is 0.1 to 1 mg (e.g., 0.1 mg, 0.5 mg, or 1 mg), 1 to 5 mg (e.g., 1 mg, 2 mg, 3 mg, 4 mg, or 5 mg), 5 to 10 mg (e.g., 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg), The amounts are 10-20 mg (e.g., 10 mg, 15 mg, or 20 mg), 20-30 mg (e.g., 20 mg, 25 mg, or 30 mg), 30-40 mg (e.g., 30 mg, 35 mg, or 40 mg), 40-50 mg (e.g., 40 mg, 45 mg, or 50 mg), 50-100 mg (e.g., 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, or 100 mg), 100-150 mg (e.g., 100 mg, 125 mg, or 150 mg), or 150-200 mg (e.g., 150 mg, 175 mg, or 200 mg), or approximately these values.In some embodiments, the therapeutic or prophylactic effective dose (e.g., per day or per dose) of a cyclosporine analog (e.g., CRV431) for treating or preventing thromboembolic disorders, for reducing or preventing thrombus formation, and / or for reducing or inhibiting prognathic platelet formation as described herein is 1 mg / kg, 1.1 mg / kg, 1.2 mg / kg, 1.3 mg / kg, 1.4 mg / kg, 1.5 mg / kg, 1.6 mg / kg, 1.7 mg / kg, 1.8 mg / kg, 1.9 mg / kg, 2 mg / kg, 2.1 mg / kg, 2.2 mg / kg, 2.3 mg / kg, 2.4 mg / kg, 2.5 mg / kg, 2.6 mg / kg, 2.7 mg / kg, 2.8 mg / kg, 2.9 mg / kg, 3 mg / kg, 3.1 mg / kg, 3.2 mg / kg, 3.3 mg / kg, 3.4 mg / kg, 3.5 mg / kg, 3.6 mg / kg, 3.7 mg / kg, 3.8 mg / kg, 3.9 mg / kg, 4 mg / kg, 4.1 mg / kg, 4.2 mg / kg, 4.3 mg / kg, 4.4 mg / kg, 4.5 mg / kg, 4.6 mg / kg, 4.7 mg / kg, 4.8 mg / kg, 4.9 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, or approximately these values, or a number or range between any two of these values. In some embodiments, the therapeutic or prophylactic effective dose of a cyclosporine analog (e.g., CRV431) is administered once or multiple times daily (e.g., two, three or more times), once every two or three days, once, two or three times weekly, or as deemed appropriate by the treating physician. In some embodiments, the composition comprises a therapeutic or prophylactic effective dose of a cyclosporine analog (e.g., CRV431) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
[0088] Cyclosporine analogs (e.g., CRV431) can also be administered in an irregular manner. For example, cyclosporine analogs (e.g., CRV431) can be administered in an irregular manner, one, two, or three times at intervals of 30 minutes, one hour, two hours, or longer. Furthermore, cyclosporine analogs (e.g., CRV431) can be taken if necessary (when needed). For example, cyclosporine analogs (e.g., CRV431) can be administered one, two, three, four, five or more times, in a regular or irregular manner, until the thromboembolic disorder / condition improves. Once relief from the thromboembolic disorder / condition is achieved, administration of cyclosporine analogs (e.g., CRV431) can be discontinued at the discretion of the patient. Once the thromboembolic disorder / condition has subsided, administration of cyclosporine analogs (e.g., CRV431) can be resumed, either regularly or irregularly. The appropriate dosage of cyclosporine analogs (e.g., CRV431), the frequency of administration, and the duration of treatment using it can be determined by the treating physician.
[0089] Cyclosporine analogs (e.g., CRV431) may also be used prophylactically to treat or prevent thromboembolic disorders, to prevent or reduce thrombus formation, or to reduce or inhibit platelet formation. The prophylactic effective dose of cyclosporine analog (e.g., CRV431) may be any therapeutic effective dose of cyclosporine analog (e.g., CRV431) as described herein.
[0090] Cyclosporine analogs (e.g., CRV431) can be administered via any suitable route. Potential routes of administration for cyclosporine analogs (e.g., CRV431) include, but are not limited to, oral, parenteral (including intramuscular, subcutaneous, intradermal, intravascular, intravenous, intraarterial, intramedullary, and subarachnoid), intracavitary, intraperitoneal, and topical (including skin / supercutaneous, percutaneous, mucous membrane, transmucosal, intranasal [e.g., by nasal spray or infusion], intraocular [e.g., by eye drops], lung [e.g., by oral or nasal inhalation], buccal, sublingual, rectal, and vaginal). In certain embodiments, cyclosporine analogs (e.g., CRV431) are administered orally (e.g., as capsules or tablets, optionally with enteric coating). In other embodiments, cyclosporine analogs (e.g., CRV431) are administered parenterally (e.g., intravenously, subcutaneously, or intradermally). In further embodiments, a cyclosporine analog (e.g., CRV431) is administered topically (e.g., transdermally / on the skin, transdermally, mucousally, transmucosally, buccally or sublingually).
[0091] In additional embodiments, the cyclosporine analog (e.g., CRV431) is administered without food. In some embodiments, the cyclosporine analog (e.g., CRV431) is administered at least about 1 or 2 hours before or after a meal. In certain embodiments, the cyclosporine analog (e.g., CRV431) is administered at least about 2 hours after dinner. The cyclosporine analog (e.g., CRV431) can also be taken substantially simultaneously with food (e.g., before or after a meal, within about 0.5 hours, 1 hour, or 2 hours, or with a meal).
[0092] In some embodiments where a more rapid establishment of a therapeutic level of a cyclosporine analog (e.g., CRV431) is desired, the cyclosporine analog (e.g., CRV431) is administered under a dosing schedule in which a loading dose is administered, followed by (i) one or more additional loading doses and then one or more therapeutically effective maintenance doses, or (ii) one or more therapeutically effective maintenance doses without additional loading doses, where deemed appropriate by the treating physician. The loading dose of the drug is typically larger than the subsequent maintenance dose (e.g., about 1.5, 2, 3, 4, or 5 times larger) and is designed to establish a therapeutic level of the drug more rapidly. One or more therapeutically effective maintenance doses may be any therapeutically effective doses described herein. In certain embodiments, the loading dose is about 3 times larger than the maintenance dose. In some embodiments, a loading dose of a cyclosporine analog (e.g., CRV431) is administered, followed by a maintenance dose of the cyclosporine analog (e.g., CRV431) after an appropriate time interval (e.g., about 12 or 24 hours) and thereafter for the duration of treatment, for example, the loading dose of the cyclosporine analog (e.g., CRV431) is administered on day 1, and the maintenance dose is administered on day 2 and thereafter for the duration of treatment. In some embodiments, a cyclosporine analog (e.g., CRV431) is administered orally (e.g., as a tablet) on day 1 in a loading dose of about 1.5 mg, 3 mg, 15 mg, or 30 mg (e.g., 3 × about 0.5 mg, 1 mg, 5 mg, or 10 mg), followed by an optional maintenance dose of about 0.5 mg, 1 mg, 5 mg, or 10 mg orally once daily (e.g., as a tablet) at bedtime for at least about 2 weeks, 1 month (4 weeks), 6 weeks, 2 months, 10 weeks, 3 months, 4 months, 5 months, 6 months, 1 year, 1.5 years, 2 years, 3 years, or longer (e.g., at least about 6 weeks, 2 months, 3 months, or 6 months).In a particular embodiment, a cyclosporine analog (e.g., CRV431) is administered orally (e.g., as a tablet) on day 1 at a loading dose of about 15 mg (e.g., 3 × about 5 mg), followed by a maintenance dose of about 5 mg orally once daily at bedtime, optionally, for at least about 2 weeks, 1 month, 6 weeks, 2 months, 3 months, 6 months, 1 year, 1.5 years, 2 years, 3 years, or longer (e.g., at least about 6 weeks, 2 months, 3 months, or 6 months).
[0093] In some embodiments, a first loading dose of a cyclosporine analog (e.g., CRV431) is administered on day 1, a second loading dose on day 2, and a maintenance dose on day 3 and thereafter for the duration of treatment. In certain embodiments, the first loading dose is about three times greater than the maintenance dose, and the second loading dose is about twice greater than the maintenance dose. As disclosed herein, therapeutic agents (e.g., cyclosporine analogs (e.g., CRV431)) can be formulated for administration in pharmaceutical compositions comprising physiologically acceptable surfactants, carriers, diluents, excipients, lubricants, suspensions, film-forming agents, coating aids, or combinations thereof. In some embodiments, therapeutic agents (e.g., cyclosporine analogs (e.g., CRV431)) are formulated for administration with pharmaceutically acceptable carriers or diluents. The therapeutic agents (e.g., cyclosporine analogs (e.g., CRV431)) can be formulated as pharmaceuticals having standard pharmaceutically acceptable carriers and / or excipients, as is common in the pharmaceutical art. The exact nature of the formulation depends on several factors, including the desired route of administration. In some embodiments, cyclosporine analogs (e.g., CRV431) are formulated for oral, intravenous, intragastric, intravascular, or intraperitoneal administration. Standard pharmaceutical formulation techniques may be used, such as those disclosed in Remington's The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins (2005), which is incorporated herein by reference in its entirety.
[0094] The terms “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” include any and all solvents, dispersions, coatings, antibacterial and antifungal agents, isotonic agents and absorption retarders, etc. The use of such media and agents for pharmaceutically active substances is well known in the art. The use of any conventional media or agent in a therapeutic composition is intended unless it is incompatible with the active ingredient. In addition, various adjuvants commonly used in the art may be included. Considerations regarding the inclusion of various components in pharmaceutical compositions are described, for example, in Gilman et al. (Eds.) (1990); Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press, which is incorporated herein by reference in its entirety. Some examples of substances that can serve as pharmaceutically acceptable carriers or components thereof include sugars, e.g., lactose, glucose, and sucrose; starches, e.g., corn starch and potato starch; cellulose and its derivatives, e.g., sodium carboxymethylcellulose, powdered tragacanth; malt; gelatin; talc; solid lubricants, e.g., stearic acid and magnesium stearate; calcium sulfate; vegetable oils, e.g., peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and theobroma oil; polyols, e.g., propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, e.g., TWEENS; wetting agents, e.g., sodium lauryl sulfate; colorants; flavoring agents; tableting agents; stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffer solution.
[0095] The selection of a pharmaceutically acceptable carrier to be used in conjunction with the subject therapeutic agent is essentially determined by the method by which the composition is to be administered. The compositions described herein are preferably provided in unit dosage forms. As used herein, “unit dosage form” is a composition containing, in accordance with good medical practice, an amount of a therapeutic agent (e.g., a cyclosporine analog (e.g., CRV431)) that is suitable for administration to an animal, preferably a mammalian subject, in a single dose. The preparation of a single or unit dosage form does not, however, imply that the dosage form is administered once per day or once per treatment cycle. Such dosage forms are intended to be administered once, twice, three or more times per day and may be administered as an infusion over a period of time (e.g., from about 30 minutes to about 2 to 6 hours) or as a continuous infusion, and may be given more than once during a treatment cycle, but single doses are not specifically excluded. Those skilled in the art will recognize that the formulation is not specifically intended for an entire treatment cycle, and that such decisions are left to those skilled in the art of treatment rather than formulation.
[0096] As described above, useful compositions may be any of various suitable forms for various routes of administration, e.g., oral, nasal, rectal, topical (including percutaneous), ocular, intracerebral, intracranial, subarachnoid, intra-arterial, intravenous, intramuscular, or other parenteral routes. Those skilled in the art will understand that oral and nasal compositions include compositions administered by inhalation and are prepared using available methodologies. Depending on the specific route of administration desired, a variety of pharmaceutically acceptable carriers well known in the art may be used. Examples of pharmaceutically acceptable carriers include solid or liquid fillers, diluents, hydrotropes, surfactants, and encapsulating materials. Optional pharmaceutically active materials that do not substantially interfere with the inhibitory activity of the therapeutic agent (e.g., cyclosporine analogs (e.g., CRV431)) may also be included. The amount of carrier used in conjunction with the therapeutic agent (e.g., a cyclosporine analog (e.g., CRV431)) is sufficient to provide a practical amount of material for administration per unit dose of the therapeutic agent (e.g., a cyclosporine analog (e.g., CRV431)). The techniques and compositions for producing useful dosage forms in the methods described herein are described in the following references, all of which are incorporated herein by reference: Modern Pharmaceutics, 4th Ed., Chapters 9 and 10 (Banker & Rhodes, editors, 2002); Lieberman et al, Pharmaceutical Dosage Forms: Tablets (1989); and Ansel, Introduction to Pharmaceutical Dosage Forms 8th Edition (2004).
[0097] Various oral dosage forms may be used, including solid forms such as tablets, capsules, and granules. Tablets may be compressed, powdered, enterically coated, sugar-coated, film-coated, or multi-compressed, containing a suitable binder, lubricant, diluent, disintegrant, colorant, flavoring agent, flow inducer, and melting agent. Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and / or suspensions restored from non-foaming granules, and effervescent preparations restored from effervescent granules, containing a suitable solvent, preservative, emulsifier, suspending agent, diluent, sweetener, melting agent, colorant, and flavoring agent. Pharmaceutically acceptable carriers suitable for the preparation of unit dosage forms for oral administration are well known in the art. Tablets typically contain conventional pharmaceutically acceptable adjuvants, such as inert diluents, e.g., calcium carbonate, sodium carbonate, mannitol, lactose, and cellulose; binders, e.g., starch, gelatin, and sucrose; disintegrants, e.g., starch, alginic acid, and croscarmellose; and lubricants, e.g., magnesium stearate, stearic acid, and talc. Flow enhancers, such as silicon dioxide, can be used to improve the flow characteristics of powder mixtures. Colorants, such as FD&C dyes, can be added for appearance. Sweeteners and flavorings, e.g., aspartame, saccharin, menthol, peppermint, and fruit flavors, are useful adjuvants for chewable tablets. Capsules typically contain one or more solid diluents disclosed above. The selection of carrier components depends on secondary considerations such as taste, cost, and storage stability, which are not critical, and can be easily done by those skilled in the art.
[0098] Oral compositions also include solutions, emulsions, and suspensions. Pharmaceutically acceptable carriers suitable for the preparation of such compositions are well known in the art. Typical components of carriers for syrups, elixirs, emulsions, and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol, and water. Typical suspending agents for suspensions include sodium carboxymethylcellulose, Avicel RC-591, tragacanth, and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methylparaben and sodium benzoate. Oral liquid compositions may also contain one or more components, such as sweeteners, flavorings, and colorants, as disclosed above.
[0099] Other compositions useful for achieving systemic delivery of the subject therapeutic agent include sublingual, buccal, and nasal dosage forms. Such compositions typically include soluble filler materials, such as sucrose, sorbitol, and mannitol; and binders, such as one or more of acacia, microcrystalline cellulose, carboxymethylcellulose, and hydroxypropylmethylcellulose. Flow enhancers, lubricants, sweeteners, colorants, antioxidants, and flavorings disclosed above may also be included. For topical use, creams, ointments, gels, solutions, or suspensions containing the therapeutic agents disclosed herein (e.g., cyclosporine analogs (e.g., CRV431)) may be used. Topical formulations generally consist of a pharmaceutical carrier, a co-solvent, an emulsifier, a penetration enhancer, a preservative system, and a emollient.
[0100] For intravenous administration, the therapeutic agents (e.g., cyclosporine analogs (e.g., CRV431)) and compositions described herein can be dissolved or dispersed in pharmaceutically acceptable diluents such as physiological saline or dextrose solution. Suitable excipients, but not limited to, include NaOH, sodium carbonate, sodium acetate, HC1, and citric acid, and may be included to achieve the desired pH. In various embodiments, the pH of the final composition is in the range of 2 to 8, or preferably 4 to 7. Examples of antioxidant excipients include sodium bisulfite, acetone bisulfite, sodium formaldehyde, sulfoxylates, thiourea, and EDTA. Other non-limiting examples of suitable excipients found in the final intravenous composition include sodium or potassium phosphate, citric acid, tartaric acid, gelatin, and carbohydrates, such as dextrose, mannitol, and dextran. Further acceptable excipients are described in Powell, et al., Compendium of Excipients for Parenteral Formulations, PDA J Pharm Sci and Tech 1998, 52 238-31 1 and Nema et al., Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions, PDA J Pharm Sci and Tech 2011, 65 287-332, both of which are incorporated herein by reference in their entirety. Antimicrobial agents may also be included, but are not limited to, mercuric phenylnitrate, thimerosal, benzethonium chloride, benzalkonium chloride, phenol, cresol, and chlorobutanol, to achieve bacteriostatic or fungal solutions.
[0101] Compositions for intravenous administration may be provided to the caregiver in one or more solid forms that are restored in water immediately before administration with a suitable diluent such as sterile water, saline, or dextrose. In other embodiments, the composition is provided as a solution ready for parenteral administration. In yet another embodiment, the composition is provided as a solution that is further diluted before administration. In embodiments involving the administration of a combination of a therapeutic agent described herein (e.g., a cyclosporine analog (e.g., CRV431)) and another agent, the combination may be provided to the caregiver as a mixture, or the caregiver may mix the two agents before administration, or the two agents may be administered separately. In non-human animal studies, the application of potential products is initiated at higher dose levels, and the dose is reduced until the desired effect is no longer achieved or adverse side effects disappear. Dosages can range broadly depending on the desired effect and therapeutic indication. Typically, doses may be between approximately 0.1 mg / kg and 4000 mg / kg body weight, preferably between approximately 80 mg / kg and 1600 mg / kg body weight. Alternatively, doses can be calculated based on the patient's surface area, as understood by those skilled in the art.
[0102] Depending on the severity and responsiveness of the condition to be treated, the medication may be a single dose of a slow-release composition, and the course of treatment may last from several days to several weeks, or until a cure is achieved or a reduction in the disease state is achieved. The amount of composition to be administered naturally depends on many factors, including the subject being treated, the severity of the pain, the method of administration, and the judgment of the prescribing physician. The therapeutic agents (e.g., cyclosporine analogs (e.g., CRV431)) or combinations of therapeutic agents disclosed herein may be administered orally or by injection in doses of 0,1 mg / kg to 4000 mg / kg of the patient's body weight per day. The dose range for adult humans is generally 1 g to 100 g / day. The tablets or other forms provided in individual units may, conveniently, contain amounts of the therapeutic agent (e.g., cyclosporine analog (e.g., CRV431)) or combinations of therapeutic agents disclosed herein, which are effective as units containing such doses or multiple doses, e.g., 1 g to 60 g (e.g., about 5 g to 20 g, about 10 g to 50 g, about 20 g to 40 g, or about 25 g to 35 g). The exact amount of therapeutic agent administered to the patient is the responsibility of the attending physician. However, the dose used depends on a number of factors, including the patient's age and sex, the exact disorder being treated, and its severity. In addition, the route of administration may vary depending on the condition and its severity. Typical doses of the therapeutic agent (e.g., cyclosporine analog (e.g., CRV431)) may be 0.02 g to 1.25 g per kg of body weight, e.g., 0.1 g to 0.5 g per kg of body weight, depending on these parameters. In some embodiments, the dosage of the therapeutic agent (e.g., cyclosporine analog (e.g., CRV431)) may range from 1 g to 100 g, for example, 10 g to 80 g, 15 g to 60 g, 20 g to 40 g, or 25 g to 35 g. A physician can determine the required dosage of the therapeutic agent (e.g., cyclosporine analog (e.g., CRV431)) for any specific patient.
[0103] The exact formulation, route of administration, and dosage for the therapeutic agents (e.g., cyclosporine analogs (e.g., CRV431)) or combinations of therapeutic agents disclosed herein may be selected by individual physicians in consideration of the patient's condition. Typically, the dose range of the composition administered to a patient may be about 0.1 mg to about 4000 mg / kg of the patient's body weight. The dosage may be a single dose or a series of two or more doses given in a one-day or multi-day cycle, as required by the patient. In examples where human doses for therapeutic agents have been established for at least some conditions, this disclosure uses those same doses, or doses between about 0.1% to about 5000%, more preferably between about 25% to about 1000%, of the established human doses. Where human doses have not been established, as in the case of newly discovered pharmaceutical compounds, an appropriate human dose may be determined by ED. 50 Value or ID 50 The value can be estimated from the value itself, or from other appropriate values derived from in vitro or in vivo studies that qualify as such through toxicity and efficacy studies in animals.
[0104] It should be noted that the attending physician knows how and when to stop, interrupt, or adjust administration in the event of toxicity or organ failure. Conversely, the attending physician has the knowledge to adjust treatment to a higher level if the clinical response is inadequate (excluding toxicity). The scale of the dose administered in the management of the disorder of interest will vary depending on the severity of the condition being treated and the route of administration. The severity of the condition can be assessed, for example, in part, by standard prognostic assessment methods. Furthermore, the dose and possibly the dose frequency will also vary according to the age, weight, and response of the individual patient. Programs comparable to those considered above can be used in veterinary medicine.
[0105] The exact dosage is determined on a drug-specific basis, but in most cases some generalization regarding dosage can be made. In the case of pharmaceutically acceptable salt administration, the dosage can be calculated as free base. In some embodiments, the composition is administered once to four times per day. Alternatively, the compositions disclosed herein can be administered by continuous intravenous infusion, for example, in doses of each active ingredient up to 100 g per day. As will be understood by those skilled in the art, in certain circumstances, particularly to effectively and invasively treat invasive diseases or infections, it may be necessary to administer the compositions disclosed herein in amounts exceeding or far exceeding the preferred dosage ranges specified above. In some embodiments, the therapeutic agents (e.g., cyclosporine analogs (e.g., CRV431)) or combinations of therapeutic agents disclosed herein are administered for a continuous treatment period, for example, one week or more, or for several months or years. In some embodiments, a drug regimen of the therapeutic agent (e.g., a cyclosporine analog (e.g., CRV431)) or combination of therapeutic agents disclosed herein is administered for a period of time, which may be, for example, at least about 1 week to at least about 4 weeks, at least about 4 weeks to at least about 8 weeks, at least about 4 weeks to at least about 12 weeks, at least about 4 weeks to at least about 16 weeks, or longer. A drug regimen of the therapeutic agent (e.g., a cyclosporine analog (e.g., CRV431)) or combination of therapeutic agents disclosed herein may be administered three times a day, twice a day, daily, every other day, three times a week, every other week, three times a month, about once a month, substantially continuously or continuously.
[0106] Cyclosporine analogs (e.g., CRV431) can be administered alone or in the form of a composition (e.g., a pharmaceutical composition). In some embodiments, the pharmaceutical composition comprises a cyclosporine analog (e.g., CRV431) or a pharmaceutically acceptable salt, solvate, hydrate, inclusion complex, polymorph, prodrug or metabolite thereof, and one or more pharmaceutically acceptable carriers or excipients. The composition may optionally contain one or more additional therapeutic agents as described herein. The pharmaceutical composition contains a therapeutically effective amount of a therapeutic agent (e.g., a cyclosporine analog (e.g., CRV431)) and one or more pharmaceutically acceptable carriers or excipients, and is formulated for administration to a subject for therapeutic use. For the purposes of the content of the pharmaceutical composition, the terms “therapeutic agent,” “active ingredient,” “active agent,” and “drug” include prodrugs.
[0107] The pharmaceutical composition contains a therapeutic agent (e.g., a cyclosporine analog (e.g., CRV431)) in a substantially pure form. In some embodiments, the purity of the therapeutic agent is at least about 95%, 96%, 97%, 98%, or 99%. In certain embodiments, the purity of the therapeutic agent is at least about 98% or 99%. In addition, the pharmaceutical composition is substantially free of foreign matter or impurities. In some embodiments, the level of residual non-solvent foreign matter or impurities in the pharmaceutical composition is about 5%, 4%, 3%, 2%, or 1% or less relative to the combined mass of the intended active and inactive components. In certain embodiments, the level of residual non-solvent foreign matter or impurities in the pharmaceutical composition is about 2% or 1% or less relative to the combined mass of the intended active and inactive components. The pharmaceutical composition is generally prepared in accordance with Good Manufacturing Practices (GMP) as recommended or required, for example, by the Federal Food, Drug, and Cosmetic Act §501(a)(2)(B) and the International Conference on Harmonization Q7 Guidelines.
[0108] Pharmaceutically acceptable carriers and excipients include pharmaceutically acceptable materials, vehicles, and substances. Non-limiting examples of excipients include liquid and solid fillers, diluents, binders, lubricants, flow enhancers, solubilizers, surfactants, dispersants, disintegrants, emulsifiers, wetting agents, suspending agents, thickeners, solvents, isotonic agents, buffers, pH adjusters, stabilizers, preservatives, antioxidants, antimicrobial agents, antibacterial agents, antifungal agents, absorption retarders, sweeteners, flavoring agents, colorants, adjuvants, encapsulating materials, and coating materials. The use of such excipients in pharmaceutical formulations is well known in the art. For example, conventional vehicles and carriers include, but are not limited to, oils (e.g., vegetable oils such as sesame oil), aqueous solvents (e.g., physiological saline, phosphate-buffered saline [PBS] and isotonic solutions [e.g., Ringer's solution]), and solvents (e.g., dimethyl sulfoxide [DMSO] and alcohols [e.g., ethanol, glycerol, and propylene glycol]). The disclosure encompasses the use of conventional carriers and excipients in formulations containing therapeutic agents (e.g., cyclosporine analogs (e.g., CRV431)), except insofar as any conventional carrier or excipient is incompatible with the active ingredient. For example, see Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins (Philadelphia, Pennsylvania
[2005] ); Handbook of Pharmaceutical Excipients, 5th Ed., Rowe et al., Eds., The Pharmaceutical Press and the American Pharmaceutical Association (2005); Handbook of Pharmaceutical Additives, 3rd Ed., Ash and Ash, Eds., Gower Publishing Co. (2007); and Pharmaceutical Preformulation and Formulation, Gibson, Ed., CRC Press (Boca Raton, Florida, 2004).
[0109] The appropriate formulation depends on various factors, including the chosen mode of administration. Potential modes of administration for pharmaceutical compositions containing cyclosporine analogs (e.g., CRV431) include, but are not limited to, oral, parenteral (including intramuscular, subcutaneous, intradermal, intravascular, intravenous, intraarterial, intraperitoneal, intramedullary, subarachnoid, and topical), intracavitary, and topical (including skin / supercutaneous, percutaneous, mucous membrane, transmucosal, intranasal [e.g., by nasal spray or infusion], lung [e.g., by oral or nasal inhalation], buccal, sublingual, rectal [e.g., by suppositories], and vaginal [e.g., by suppositories]). For example, formulations of cyclosporine analogs suitable for oral administration (e.g., CRV431) may exist, for example, as boluses; as tablets, capsules, pills, cachets or lozenges; as powders or granules; as semi-solids, licks, pastes or gels; as solutions or suspensions in aqueous and / or non-aqueous liquids; or as oil-in-water or water-in-oil liquid emulsions.
[0110] The tablets may contain a cyclosporine analog (e.g., CRV431) in an additive mixture with, for example, a filler or inert diluent (e.g., calcium carbonate, calcium phosphate, lactose, mannitol, or microcrystalline cellulose), a binder (e.g., starch, gelatin, acacia, alginic acid or its salts, or microcrystalline cellulose), a lubricant (e.g., stearic acid, magnesium stearate, talc, or silicon dioxide), and a disintegrant (e.g., crospovidone, croscarmellose sodium, or colloidal silica), and optionally a surfactant (e.g., sodium lauryl sulfate). The tablets may be uncoated, or they may be coated with, for example, an enteric coating to protect the active ingredient from the acidic environment of the stomach, or with a material that delays the disintegration and absorption of the active ingredient in the gastrointestinal tract, thereby providing a sustained action over a longer period of time. In certain embodiments, the tablets comprise a cyclosporine analog (e.g., CRV431), mannitol, microcrystalline cellulose, magnesium stearate, silicon dioxide, croscarmellose sodium, and sodium lauryl sulfate, and optionally lactose monohydrate, and the tablets are optionally film-coated (e.g., using Opadry®).
[0111] Push-in capsules or two-piece hard gelatin capsules may contain, for example, a cyclosporine analog (e.g., CRV431) in an additive mixture with a filler or inert solid diluent (e.g., calcium carbonate, calcium phosphate, kaolin, or lactose), a binder (e.g., starch), a flow enhancer or lubricant (e.g., talc or magnesium stearate), and a disintegrant (e.g., crospovidone), and optionally a stabilizer or / and preservative. For soft capsules or single-piece gelatin capsules, the cyclosporine analog (e.g., CRV431) may be dissolved or suspended in a suitable liquid (e.g., liquid polyethylene glycol or an oil medium, e.g., fatty oil, peanut oil, olive oil, or liquid paraffin), and liquid-filled capsules may contain one or more other liquid excipients or / and semi-solid excipients, e.g., stabilizers or / and amphiphilic agents (e.g., fatty acid esters of glycerol, propylene glycol, or sorbitol).
[0112] Compositions for oral administration may also be formulated as solutions or suspensions in aqueous and / or non-aqueous liquids, or as oil-in-water or water-in-oil liquid emulsions. Dispersible powders or granules of cyclosporine analogs (e.g., CRV431) can be mixed with aqueous liquids, organic solvents and / or oils, and any suitable combination of suitable excipients (e.g., any combination of dispersants, wetting agents, suspending agents, emulsifiers, and / or preservatives) to form solutions, suspensions, or emulsions. Cyclosporine analogs (e.g., CRV431) can also be formulated for parenteral administration by injection or infusion to avoid gastrointestinal absorption and first-pass metabolism. The most common parenteral route is intravenous.
[0113] Additional advantages of intravenous administration include the direct delivery of the therapeutic agent into the systemic circulation to achieve a rapid systemic effect, and the ability to administer the drug continuously and / or in larger volumes if desired. Formulations for injection or infusion may be in the form of solutions, suspensions, or emulsions in oily or aqueous vehicles, and may contain excipients such as suspending agents, dispersants, and / or stabilizers. For example, an aqueous or non-aqueous (e.g., oily) sterile injection solution may contain a cyclosporine analog (e.g., CRV431) together with excipients such as antioxidants, buffers, bacteriostatic agents, and solutes to make the formulation isotonic with the blood of the subject. An aqueous or non-aqueous sterile suspension may contain a cyclosporine analog (e.g., CRV431) together with excipients such as suspending agents and thickeners, and optionally stabilizers, and agents that increase the solubility of the cyclosporine analog (e.g., CRV431) to enable the preparation of more concentrated solutions or suspensions. As another example, a sterile aqueous solution for injection or infusion (e.g., subcutaneous or intravenous) may contain a cyclosporine analog (e.g., CRV431), NaCl, a buffer (e.g., sodium citrate), a preservative (e.g., meta-cresol), and optionally, a base (e.g., NaOH) or / and an acid (e.g., HC1) to adjust the pH.
[0114] For local administration, cyclosporine analogs (e.g., CRV431) can be formulated, for example, as buccal or sublingual tablets or pills. Advantages of buccal or sublingual tablets or pills include avoidance of first-pass metabolism and gastrointestinal absorption. Buccal or sublingual tablets or pills can also be designed to provide faster release of cyclosporine analogs (e.g., CRV431) for more rapid uptake into the systemic circulation. In addition to a therapeutically effective amount of cyclosporine analog (e.g., CRV431), buccal or sublingual tablets or pills may contain, without limitation, any combination of fillers and diluents (e.g., mannitol and sorbitol), binders (e.g., sodium carbonate), wetting agents (e.g., sodium carbonate), disintegrants (e.g., crospovidone and croscarmellose sodium), lubricants (e.g., silicon dioxide [including colloidal silicon dioxide] and sodium stearyl fumarate), stabilizers (e.g., sodium bicarbonate), flavoring agents (e.g., spearmint flavor), sweeteners (e.g., sucralose), and colorants (e.g., yellow iron oxide).
[0115] For local administration, cyclosporine analogs (e.g., CRV431) can also be formulated for intranasal administration. The nasal mucosa offers a large surface area, porous endothelium, highly vascularized subepithelial layer, and high absorption rate, thus enabling high bioavailability. Furthermore, intranasal administration avoids first-pass metabolism and allows significant concentrations of cyclosporine analogs (e.g., CRV431) to be introduced into the central nervous system, enabling the cyclosporine analog (e.g., CRV431) to block the central cough reflex via the nucleus tractus solitarius in the cough center of the medulla oblongata, where afferent vagus nerves are terminated. Intranasal solutions or suspension formulations may contain a cyclosporine analog (e.g., CRV431) together with excipients such as a solubility enhancer (e.g., propylene glycol), a water-retaining agent (e.g., mannitol or sorbitol), a buffer, and water, and optionally a preservative (e.g., benzalkonium chloride), a mucosal adhesion agent (e.g., hydroxyethylcellulose), and / or an osmotic enhancer. In certain embodiments, a nasal spray formulation may contain a cyclosporine analog (e.g., CRV431), microcrystalline cellulose, sodium carboxymethylcellulose, dextrose, and water, and optionally an acid (e.g., HC1) for pH adjustment. Intranasal solutions or suspension formulations may be administered into the nasal cavity by any suitable means, including, but not limited to, a dropper, pipette, or spray using, for example, a measuring spray pump.
[0116] Additional modes of local administration include oral and nasal inhalation, as detailed below, and are administered to the lungs. Other suitable topical formulations and dosage forms include, but are not limited to, ointments, creams, gels, lotions, and pastes, as described in Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins (Philadelphia, Pennsylvania, 2005). Ointments are typically semi-solid preparations based on petrolatum or petroleum derivatives. Creams are viscous liquids or semi-solid emulsions, and are either oil-in-water or water-in-oil. Cream bases are washable and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase, also called the “internal” phase, generally contains petrolatum and fatty alcohols (e.g., cetyl or stearyl alcohol). The aqueous phase typically, but not always, exceeds the volume of the oil phase and usually contains a hydrating agent. Emulsifiers in cream formulations are generally nonionic, anionic, cationic, or amphoteric surfactants. Gels are semi-solid, suspension systems. Single-phase gels contain organic macromolecules (polymers) substantially uniformly distributed throughout a carrier liquid, which is typically aqueous but may also contain alcohols (e.g., ethanol or isopropanol) and optionally oils. A lotion is a preparation that should be applied to the skin surface without friction, and is typically a liquid or semi-liquid preparation in which solid particles containing the active agent are present in water or an alcoholic base. A lotion is usually a suspension of finely powdered solids and typically contains a suspending agent to produce a better dispersion and compounds useful for localizing and maintaining the active agent in contact with the skin. A paste is a semi-solid dosage form in which the active agent is suspended in a suitable base. Depending on the properties of the base, pastes can be divided into those made of fatty pastes or monophase aqueous gels.
[0117] Various excipients may be included in topical formulations. For example, solvents, including appropriate amounts of alcohol, can be used to solubilize the active agent. Other optional excipients include, but are not limited to, gelling agents, thickeners, emulsifiers, surfactants, stabilizers, buffers, antioxidants, preservatives, coolants (e.g., menthol), opacifiers, fragrances, and colorants. For active agents that have a low rate of permeation through skin or mucous membrane tissue, topical formulations may contain permeation enhancers to increase the permeation of the active agent through skin or mucous membrane tissue. Topical formulations may also contain irritation-reducing excipients to reduce any irritation to the skin or mucous membrane caused by the active agent, permeation enhancer, or any other component of the formulation.
[0118] In some embodiments, a cyclosporine analog (e.g., CRV431) is delivered from a sustained-release composition. As used herein, the term “sustained-release composition” encompasses sustained-release, prolonged-release, extended-release, slow-release, and controlled-release compositions, systems, and devices. The use of sustained-release compositions can have benefits such as improved profiles of the amount of drug or its active metabolite delivered to a target site over a period of time, including the delivery of therapeutically effective amounts of the drug or its active metabolite over a long period of time. In certain embodiments, the sustained-release composition delivers a cyclosporine analog (e.g., CRV431) over a period of at least about 1 day, 2 days, 3 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, or longer. In some embodiments, the sustained-release composition is a drug encapsulation system such as nanoparticles, microparticles, or capsules made from, for example, biodegradable polymers and / or hydrogels. In certain embodiments, the sustained-release composition comprises a hydrogel. Non-limiting examples of polymers that can constitute a hydrogel include polyvinyl alcohol, acrylate polymers (e.g., sodium polyacrylate), and other homopolymers and copolymers having a relatively large number of hydrophilic groups (e.g., hydroxyl groups and / or carboxylate groups). In other embodiments, the sustained-release drug encapsulation system comprises a membrane-encapsulated reservoir, where the reservoir contains the drug and the membrane is permeable to the drug. Such drug delivery systems may be in the form of, for example, a transdermal patch.
[0119] In some embodiments, the sustained-release composition is in the form of an oral dosage, such as a tablet or capsule. For example, the drug may be embedded in an insoluble porous matrix, so that the drug must pass through the matrix and exit before it can be absorbed through the gastrointestinal tract. Alternatively, the drug may be embedded in a matrix that expands to form a gel from which the drug is released. Furthermore, sustained release may be achieved via a single-layer or multi-layer osmotically controlled release oral delivery system (OROS). An OROS is a tablet having a semipermeable outer membrane and one or more small laser-drilled holes therein. As the tablet passes through the body, water is absorbed through the semipermeable membrane via osmosis, and the resulting osmotic pressure pushes the drug out of the holes in the tablet into the gastrointestinal tract, where it can be absorbed. In further embodiments, the sustained-release composition is formulated as polymeric nanoparticles or microparticles, where the polymeric particles can be delivered, for example, by inhalation or injection, or from a graft. In some embodiments, the polymeric graft or polymeric nanoparticles or microparticles are composed of a biodegradable polymer. In certain embodiments, the biodegradable polymer includes lactic acid and / or glycolic acid [e.g., L-lactic acid-based copolymers such as poly(L-lactide-co-glycolide) or poly(L-lactic acid-co-D,L-2-hydroxyoctanoic acid)]. For example, biodegradable polymeric microspheres composed of polylactic acid and / or polyglycolic acid can serve as a sustained-release pulmonary drug delivery system. The biodegradable polymer of the polymeric graft or polymeric nanoparticles or microparticles can be selected such that the polymer degrades substantially completely around the time the treatment period is expected to end, and that the by-products of polymer degradation are biocompatible, as are the polymers themselves.
[0120] For delayed or sustained release of cyclosporine analogs (e.g., CRV431), the composition may also be formulated as a depot that can be implanted or injected into a subject, for example, intramuscularly or subcutaneously. The depot formulation can be designed to deliver cyclosporine analogs (e.g., CRV431) over longer periods, for example, over at least about 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 2 months, 3 months, or longer. For example, cyclosporine analogs (e.g., CRV431) can be formulated with polymer materials (e.g., polyethylene glycol (PEG), polylactic acid (PLA), or polyglycolic acid (PGA), or their copolymers (e.g., PLGA)), hydrophobic materials (e.g., as an emulsion in oil) and / or ion exchange resins, or as a slightly soluble derivative (e.g., a slightly soluble salt). As an exemplary example, a cyclosporine analog (e.g., CRV431) can be incorporated into or embedded in sustained-release microparticles composed of PLGA and formulated as a one-month depot. Cyclosporine analogs (e.g., CRV431) can also be contained in or dispersed in the matrix material. The matrix material may include a polymer (e.g., ethylene-vinyl acetate) and can control the release of the compound, for example, by controlling the dissolution and / or diffusion of the compound from the reservoir, and can enhance the stability of the compound while it is contained in the reservoir. Such release systems can be designed as sustained-release systems and can be configured, for example, as a transdermal or transmucosal patch, and may contain excipients that can accelerate the release of the compound, such as a water-swellable material (e.g., hydrogel) that helps to expel the compound from the reservoir.
[0121] The release system can provide a time-modulated release profile (e.g., pulsatile release) when time variation in plasma levels is desired, or a more continuous or constant release profile when a constant plasma level is desired. Pulsatile release can be achieved from individual reservoirs or from multiple reservoirs. For example, if each reservoir provides a single pulse, multiple pulses ("pulsatile" release) can be achieved by temporally staggering single-pulse releases from each of the multiple reservoirs. Alternatively, multiple pulses can be achieved from a single reservoir by incorporating several layers of emission systems and other materials into a single reservoir. Continuous emission can be achieved by incorporating an emission system that allows for the decomposition, dissolution, or diffusion of a compound through it over a long period of time. In addition, continuous emission can be approximated by rapidly and continuously ("digital") emitting several pulses of a compound. Active emission systems can be used alone or in combination with passive emission systems, as described in U.S. Patent No. 5,797,898.
[0122] In addition, pharmaceutical compositions containing cyclosporine analogs (e.g., CRV431) can be formulated, for example, as liposomes, micelles (e.g., lactosomes, which are composed of biodegradable natural and / or synthetic polymers), microspheres, microparticles, or nanoparticles, whether or not they are designed for sustained release. Pharmaceutical compositions can be manufactured by any suitable method known in the art, for example, by conventional mixing, dissolving, suspending, granulating, sugar-coating, polishing, emulsifying, encapsulating, incorporating, or compressing processes. Pharmaceutical compositions can exist in unit dosage forms as a single dose in which all active and inactive components are combined in a suitable system, and the components do not need to be mixed to form the composition to be administered. A unit dosage form may contain an effective dose of a therapeutic agent (e.g., a cyclosporine analog (e.g., CRV431)) or a suitable fraction thereof. Typical examples of unit dosage forms include tablets, capsules, or pills for oral administration, and powders in vials or ampoules for oral or nasal inhalation.
[0123] Alternatively, the pharmaceutical composition may exist as a kit, where the active ingredient, excipients, and carrier (e.g., solvent) are provided in two or more separate containers (e.g., ampoules, vials, tubes, bottles, or syringes) and do not need to be combined to form the composition to be administered. The kit may contain instructions for storing, preparing, and administering the composition (e.g., a solution to be injected intravenously). The kit may contain all active and inactive components in a single dosage form, or in two or more separate containers, and may include instructions for using the pharmaceutical composition. In some embodiments, the kit contains a cyclosporine analog (e.g., CRV431) or a pharmaceutically acceptable salt, solvate, hydrate, inclusion complex, polymorph, prodrug or metabolite thereof, and instructions for administering the compound. [Examples]
[0124] Some aspects of the embodiments discussed above are disclosed in further detail in the following embodiments, which are not intended to limit the scope of this disclosure in any way. (Example 1) Effects of CRV431 on platelet aggregation and prognathic platelet formation In this embodiment, the broad-spectrum cyclophyllin inhibitor, CRV431, is evaluated to determine whether it can inhibit human platelet aggregation and / or protozoal formation.
[0125] method Platelet isolation. Blood (40 ml) was obtained from healthy volunteers who had not taken any drugs known to affect platelet function two weeks prior to the study. Platelet suspension (2.5 × 10⁶) washed with prostacyclin. 8 The solution ( / ml) was prepared in Tyrode's buffer. Platelet aggregation measurement. Washed platelets (500 μl / test) were pre-incubated in a Lumi agglutinator (Chronolog, Havertown, PA, USA) using either a vehicle (0.1% DMSO) or CRV431 (0.01-3 μM) (2 minutes at 37°C). Platelet aggregation was then induced with collagen (1 μg / mL) or thrombin (0.1 U / mL) (Chronolog), and monitored for a further 6 minutes using Aggro-Link software. The degree of platelet aggregation was measured as the light transmittance % between 2 minutes and 6 minutes and determined using Aggro-Link software.
[0126] Coagulation progenitor platelet formation study. Washed platelets (100 μl / test) were pre-incubated with CRV431 (0.01-3 μM) (2 minutes at 37°C), then activated with combined collagen (10 μg / mL) and thrombin (0.1 U / mL), and incubated for a further 10 minutes. Coagulation progenitor platelet formation was determined by flow cytometry, as previously described, by measuring annexin-V-FITC bound to exposed phosphatidylserine (PS). Flow cytometry was performed using a BD Fortessa X20 flow cytometer equipped with a blue (488 nm) laser and a 530 / 30 bandpass filter to detect FITC. After acquisition using FlowJo software, the percentage of PS-positive platelets was determined. Statistics. Statistical analysis was performed using GraphPad Prism 7.0 software. All methods are reported using SEM. One-way ANOVA with Dunnett's multiple comparison test was performed for agglutination studies, and repeated-measures one-way ANOVA with Dunnett's multiple comparison test was performed for platelet formation studies. Each N represents an experiment from an independent blood donor. A P value of less than 0.05 was considered significant.
[0127] result CRV431 did not inhibit collagen or thrombin-induced platelet aggregation at any of the tested concentrations (CRV431 0.01–3 μM) (Figures 1A–B and 2A–B). As a positive control, the gold standard antiplatelet drug, acetylsalicylic acid, effectively inhibited aggregation (Figure 3A–B). However, CRV431 at 1 μM and 3 μM significantly inhibited platelet PS exposure and markers of protozoan platelet formation when activated by collagen and thrombin (Figure 4A–B). Data for platelet PS exposure in the presence of Coll 1 μg / ml–Thr 0.1 U / ml and Coll 10 μg / ml–Thr 0.1 U / ml are shown in Figures 5A and 5B, respectively.
[0128] Consideration It has been demonstrated that prognathic platelets are elevated in thrombotic diseases. The results shown in this example indicate that CRV431 is a novel antithrombotic agent that blocks platelet-mediated coagulation via cyclophylline inhibition but does not inhibit platelet aggregation. In at least some of the embodiments described above, one or more elements used in one embodiment may be used interchangeably in another embodiment, insofar as such substitutions are technically feasible. Those skilled in the art will understand that various other omissions, additions, and modifications may be made to the methods and structures described above without departing from the scope of the claimed subject matter. All such modifications and variations are intended to fall within the scope of the subject matter as defined by the appended claims.
[0129] With regard to the use of substantially any plural and / or singular terms herein, those skilled in the art may convert from plural to singular and / or singular to plural as appropriate to the context and / or use. Various singular / plural substitutions may be clearly described herein for clarity. Where used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly indicates otherwise. Any reference to "or" herein is intended to include "and / or" unless otherwise specified.
[0130] In general, the terms used herein, and especially in the appended claims (e.g., the body of the appended claims), will be understood by those skilled in the art to be generally intended as “open” terms (for example, the term “including” should be interpreted as “including but not limited,” the term “having” should be interpreted as “having at least,” the term “containing” should be interpreted as “containing but not limited,” and so on). If a particular number of claims enumerations is intended, such intent will be explicitly enumerated in the claims, and in the absence of such enumerations, such intent will not be present, will be understood by those skilled in the art to further understand. For example, for the sake of understanding, the following appended claims may include the use of the prefatory phrases “at least one” and “one or more” to introduce a claim enumeration. However, the use of such phrases should not be interpreted as implying that the introduction of a claim enumeration with the indefinite article "a" or "an" limits any particular claim containing such introduced claim enumeration to only one embodiment containing such enumeration, even if the same claim contains a prefatory phrase such as "one or more" or "at least one" and an indefinite article such as "a" or "an" (for example, "a" and / or "an" should be interpreted as meaning "at least one" or "one or more"); the same is true for the use of the definite article used to introduce a claim enumeration. In addition, even if a specific number of introduced claim enumerations is explicitly listed, a person skilled in the art will recognize that such enumerations should be interpreted as meaning at least the number listed (for example, the literal enumeration of "two enumerations" without other modifiers means at least two enumerations or two or more enumerations). Furthermore, in examples where a convention similar to "at least one of A, B, and C" is used, such constructions are generally intended to be understood by those skilled in the art (for example, "a system having at least one of A, B, and C" includes, but is not limited to, a system having A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or a system having A, B, and C together).In examples where conventions similar to "at least one of A, B, or C" are used, such constructions are generally intended to be understood by those skilled in the art (for example, "a system having at least one of A, B, or C" includes, but is not limited to, A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or a system having A, B, and C together). It will be further understood by those skilled in the art that substantially any disjunctive word and / or phrase presenting two or more alternative terms should be understood to intend the possibility of including one of the terms, either of the terms, or both of the terms, even in the specification, claims, or drawings.
[0131] In addition, if any feature or aspect of this disclosure is described from the perspective of the Markush Group, a person skilled in the art will recognize that the disclosure is also described from the perspective of any individual member or subgroup of a member of the Markush Group. As will be understood by those skilled in the art, for any and all purposes, for example, in terms of providing written information, all scopes disclosed herein also encompass any and all possible subscopes and combinations thereof. Any listed scope can be readily recognized as sufficiently describing and enabling that the same scope may be divided into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each scope considered herein can be readily divided into a lower third, a middle third, an upper third, etc. Furthermore, as will be understood by those skilled in the art, all terms such as “maximum,” “at least,” “greater than,” and “less than” include the listed numbers and refer to scopes that can be subsequently divided into subscopes as considered above. Finally, as will be understood by those skilled in the art, a scope includes each individual member. Thus, for example, a group having 1 to 3 items refers to a group having one, two, or three items. Similarly, a group having 1 to 5 items refers to a group having one, two, three, four, or five items, and so on.
[0132] While various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for illustrative purposes only and are not intended to be limiting, and the true scope and spirit are shown by the following claims.
Claims
1. A composition for use in a method for treating a thromboembolic disorder or a method for the primary or secondary prevention of a thromboembolic disorder by selectively inhibiting the formation of procoagulant platelets in a subject in need thereof, comprising administering to the subject a composition comprising a cyclosporine analog of formula L, or a pharma- ceutically acceptable salt, solvate, or stereoisomer thereof. 【Chemistry 1】 (In the formula: a. R' is H or acetyl; b. R1 is a saturated or unsaturated, straight or branched aliphatic carbon chain of 2 to 15 carbon atoms in length; c. R2 is selected from the group consisting of: i.H; ii. unsubstituted, N-substituted or N,N-disubstituted amides; iii. N-substituted or unsubstituted acyl protected amines; iv. N-substituted or unsubstituted amines; v. carboxylic acid; vi. nitrile; vii. esters; viii. ketones; ix. hydroxy, dihydroxy, trihydroxy or polyhydroxyalkyl; and x. substituted or unsubstituted aryl; xi. a saturated or unsaturated, straight or branched aliphatic chain which may contain a substituent selected from the group consisting of hydrogen, ketone, hydroxyl, nitrile, carboxylic acid, ester, 1,3-dioxolane, halogen and oxo; xii. an aromatic group containing a substituent selected from the group consisting of halogen, ester, and nitro; and xiii. A combination of (xi) a saturated or unsaturated, linear or branched aliphatic chain and (xii) an aromatic group; d. R23 is a saturated or unsaturated, straight or branched, optionally substituted aliphatic carbon chain.
2. The composition of claim 1, wherein the thromboembolic disorder is an arterial cardiovascular thromboembolic disorder, a venous cardiovascular thromboembolic disorder, or a thromboembolic disorder in the ventricles or in the peripheral circulation, unstable angina, acute coronary syndrome, myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary artery thrombosis, cerebral artery thrombosis, cerebral embolism, renal embolism, pulmonary embolism, or thrombosis due to a medical implant, device or procedure in which blood is exposed to an artificial surface that promotes thrombosis, abrupt closure following angioplasty or stent placement, thrombosis induced by peripheral vascular surgery or peripheral vascular disease, or a thrombotic disorder due to atrial fibrillation or inflammation.
3. (a) The method comprising: (i) reducing thrombus formation in said subject by at least 5%, 10%, 20%, 50%, 70%, 90% or more; or (ii) delaying or reducing the likelihood of thrombus formation in said subject; or (iii) preventing or delaying the onset of thrombus formation in said subject; or (iv) reducing the risk of bleeding in said subject by at least 5%, 10%, 20%, 50%, 70%, 90% or more; and / or (b) platelet aggregation is not inhibited in the subject. The composition according to claim 1 or 2.
4. A composition for use in a method for reducing or preventing thrombus formation or a method for reducing or preventing the formation of procoagulant platelets in a subject in need thereof by selectively inhibiting the formation of procoagulant platelets, comprising administering to said subject a composition comprising a cyclosporine analog of formula L, or a pharma- ceutically acceptable salt, solvate, or stereoisomer thereof. 【Chemistry 2】 (In the formula: a. R' is H or acetyl; b. R1 is a saturated or unsaturated, straight or branched aliphatic carbon chain of 2 to 15 carbon atoms in length; c. R2 is selected from the group consisting of: i.H; ii. unsubstituted, N-substituted or N,N-disubstituted amides; iii. N-substituted or unsubstituted acyl protected amines; iv. N-substituted or unsubstituted amines; v. carboxylic acid; vi. nitrile; vii. esters; viii. ketones; ix. hydroxy, dihydroxy, trihydroxy or polyhydroxyalkyl; and x. substituted or unsubstituted aryl; xi. a saturated or unsaturated, straight or branched aliphatic chain which may contain a substituent selected from the group consisting of hydrogen, ketone, hydroxyl, nitrile, carboxylic acid, ester, 1,3-dioxolane, halogen and oxo; xii. an aromatic group containing a substituent selected from the group consisting of halogen, ester, and nitro; and xiii. A combination of (xi) a saturated or unsaturated, linear or branched aliphatic chain and (xii) an aromatic group; d. R23 is a saturated or unsaturated, straight or branched, optionally substituted aliphatic carbon chain.
5. The composition of claim 4, wherein platelet aggregation is not reduced.
6. The subject is a subject suffering from or at risk of developing a prothrombotic or thrombotic condition, 6. The composition of claim 4 or 5, wherein optionally the prothrombotic or thrombotic condition is selected from the group consisting of infection, sepsis, systemic inflammatory response syndrome, multiple organ failure, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, angiogenesis, renal failure, ischemic rebound injury, solid organ transplant rejection, cardiovascular disease, stroke, venous thromboembolism, autoimmune disorders, sickle cell disease, inflammatory bowel disease, acute lung injury, malignancy, myocardial infarction (primary and secondary), embolic stroke, ischemic stroke, thrombotic stroke, deep vein thrombosis (DVT), thromboembolism, portal vein thrombosis, renal vein thrombosis, jugular vein thrombosis, Budd-Chiari syndrome, Paget-Schletter syndrome, cerebral venous sinus thrombosis, arterial thrombosis, and arterial embolism. (a) the cyclosporine analog is CRV431; and / or (b) the composition comprises a therapeutically or prophylactically effective amount of a cyclosporine analog; and / or (c) the subject is a mammal, optionally the subject may be a human; and / or (d) the composition comprises one or more pharma- ceutically acceptable excipients; The composition according to any one of claims 1 to 6.
8. The composition further comprising one or more additional therapeutic agents; or The composition of any one of claims 1 to 7, wherein the method further comprises administering to the subject one or more additional therapeutic agents. (a) the one or more additional therapeutic agents comprises an anticoagulant, an antiplatelet agent, a fibrinolytic agent, or a combination thereof; Optionally, the one or more additional therapeutic agents may comprise heparin, low molecular weight heparin, bivalirudin, fondaparinux, warfarin, acenocoumarol, phenprocoumon, phenindione, avokinase (urokinase), streptokinase, alteplase, retaplase, tenecteplase, prasugrel, aspirin, ticlopidine, clopidogrel, abciximab, eptifibatide, tirofiban, or combinations thereof; and / or (b) at least one of the one or more additional therapeutic agents is co-administered to the subject with the composition; or at least one of the one or more additional therapeutic agents is administered to the subject prior to administration of the composition, after administration of the composition, or both; The composition of claim 8. (a) the composition is formulated for administration to the subject by intravenous, oral or parenteral administration, optionally, the composition is formulated for administration to the subject by oral or intravenous administration; and / or (b) the composition is in the form of a powder, a pill, a tablet, a microtablet, a pellet, a micropellet, a capsule, a capsule containing microtablets, a liquid, a stable self-emulsifying drug delivery system (SMEDD), an aerosol or nanoparticles; and / or (c) the composition is administered to the subject at an effective daily dose of the cyclosporine analog, or a pharma- ceutically acceptable salt, solvate, or stereoisomer thereof, between 10 mg and 250 mg; The composition according to any one of claims 1 to 9.
11. A cyclosporine analog of formula L, or a pharma- ceutically acceptable salt, solvate, stereoisomer or composition thereof: 【Chemistry 4】 (In the formula: a. R' is H or acetyl; b. R1 is a saturated or unsaturated, straight or branched aliphatic carbon chain of 2 to 15 carbon atoms in length; c. R2 is selected from the group consisting of: i.H; ii. unsubstituted, N-substituted or N,N-disubstituted amides; iii. N-substituted or unsubstituted acyl protected amines; iv. N-substituted or unsubstituted amines; v. carboxylic acid; vi. nitrile; vii. esters; viii. ketones; ix. hydroxy, dihydroxy, trihydroxy or polyhydroxyalkyl; and x. substituted or unsubstituted aryl; xi. a saturated or unsaturated, straight or branched aliphatic chain which may contain a substituent selected from the group consisting of hydrogen, ketone, hydroxyl, nitrile, carboxylic acid, ester, 1,3-dioxolane, halogen and oxo; xii. an aromatic group containing a substituent selected from the group consisting of halogen, ester, and nitro; and xiii. A combination of (xi) a saturated or unsaturated, linear or branched aliphatic chain and (xii) an aromatic group; d. R23 is a saturated or unsaturated, straight or branched, optionally substituted aliphatic carbon chain. and Indication indicating that the kit is for one or more of: (i) a method of preventing or treating a thromboembolic disorder, (ii) a method of reducing or preventing thrombus formation, and (iii) a method of reducing or inhibiting procoagulant platelet formation by inhibiting procoagulant platelet formation in a subject in need thereof. Kit including:
12. (a) the thromboembolic disorder is an arterial cardiovascular thromboembolic disorder, a venous cardiovascular thromboembolic disorder, or a thromboembolic disorder in the ventricles or in the peripheral circulation, unstable angina, acute coronary syndrome, myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary artery thrombosis, cerebral artery thrombosis, cerebral embolism, renal embolism, pulmonary embolism, or thrombosis due to a medical implant, device or procedure in which blood is exposed to an artificial surface that promotes thrombosis, abrupt closure following angioplasty or stent placement, thrombosis induced by peripheral vascular surgery or peripheral vascular disease, or a thrombotic disorder due to atrial fibrillation or inflammation; or (b) the subject suffers from or is at risk of developing a prothrombotic or thrombotic condition; Optionally, the prothrombotic or thrombotic condition is selected from the group consisting of infection, sepsis, systemic inflammatory response syndrome, multiple organ failure, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, angiogenesis, renal failure, ischemic rebound injury, solid organ transplant rejection, cardiovascular disease, stroke, venous thromboembolism, autoimmune disorders, sickle cell disease, inflammatory bowel disease, acute lung injury, malignancy, myocardial infarction (primary and secondary), embolic stroke, ischemic stroke, thrombotic stroke, deep vein thrombosis (DVT), thromboembolism, portal vein thrombosis, renal vein thrombosis, jugular vein thrombosis, Budd-Chiari syndrome, Paget-Schletter syndrome, cerebral sinus thrombosis, arterial thrombosis, and arterial embolism. The kit of claim 11. (a) the cyclosporine analog is CRV431; and / or (b) the label includes instructions for administering a therapeutically or prophylactically effective amount of the cyclosporine analog; and / or (c) the subject is a mammal, optionally wherein the subject is a human; and / or (d) the composition comprises one or more pharma- ceutically acceptable excipients; and / or (e) the instructions include instructions for administering the cyclosporine analog to the subject by intravenous, oral, or parenteral administration; Optionally, the instructions may include instructions for administering the cyclosporine analogue to the subject by oral or intravenous administration; and / or (f) the cyclosporine analog is in the form of a powder, a pill, a tablet, a microtablet, a pellet, a micropellet, a capsule, a capsule containing microtablets, a liquid, a stable self-emulsifying drug delivery system (SMEDD), an aerosol, or nanoparticles; and / or 13. The kit of claim 11 or 12, wherein (g) the instructions include instructions for administering the cyclosporine analog to the subject at an effective daily dose of the cyclosporine analog, or a pharma- ceutically acceptable salt, solvate, or stereoisomer thereof, from 10 mg to 250 mg.
14. A kit described in any one of claims 11 to 13, wherein the label includes instructions for administering the cyclosporine analog together with one or more additional therapeutic agents, and optionally, the kit may further include one or more of the one or more additional therapeutic agents.
15. The method of claim 1, wherein the one or more additional therapeutic agents comprises an anticoagulant, an antiplatelet agent, a fibrinolytic agent, or a combination thereof; Optionally, the one or more additional therapeutic agents may comprise heparin, low molecular weight heparin, bivalirudin, fondaparinux, warfarin, acenocoumarol, phenprocoumon, phenindione, avokinase (urokinase), streptokinase, alteplase, retaplase, tenecteplase, prasugrel, aspirin, ticlopidine, clopidogrel, abciximab, eptifibatide, tirofiban, or combinations thereof; and / or (b) the instructions include instructions for co-administering to the subject at least one of the one or more additional therapeutic agents with the cyclosporine analog; or the instructions include instructions for administering to the subject at least one of the one or more additional therapeutic agents prior to administration of the cyclosporine analog to the subject, after administration of the cyclosporine analog to the subject, or both. The kit of claim 14.
